CN111138301B - 联苯类化合物、其中间体、制备方法、药物组合物及应用 - Google Patents
联苯类化合物、其中间体、制备方法、药物组合物及应用 Download PDFInfo
- Publication number
- CN111138301B CN111138301B CN201911023996.7A CN201911023996A CN111138301B CN 111138301 B CN111138301 B CN 111138301B CN 201911023996 A CN201911023996 A CN 201911023996A CN 111138301 B CN111138301 B CN 111138301B
- Authority
- CN
- China
- Prior art keywords
- substituted
- alkyl
- compound
- ring
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Biphenyl compound Chemical class 0.000 title claims abstract description 86
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 239000004305 biphenyl Substances 0.000 title claims abstract description 54
- 235000010290 biphenyl Nutrition 0.000 title claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 161
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 74
- 150000002367 halogens Chemical class 0.000 claims description 74
- 125000001424 substituent group Chemical group 0.000 claims description 71
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 43
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 125000006239 protecting group Chemical group 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 15
- 229910052805 deuterium Inorganic materials 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000002015 acyclic group Chemical group 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 3
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims description 3
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 claims description 3
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims description 3
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 claims description 3
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 3
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims description 3
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 3
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract description 17
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 55
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 47
- 125000001072 heteroaryl group Chemical group 0.000 description 47
- 238000003786 synthesis reaction Methods 0.000 description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 238000010898 silica gel chromatography Methods 0.000 description 28
- 239000003208 petroleum Substances 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 25
- 125000000547 substituted alkyl group Chemical group 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000011259 mixed solution Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000000304 alkynyl group Chemical group 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 125000005415 substituted alkoxy group Chemical group 0.000 description 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- JPJGNZQDELRZGE-UHFFFAOYSA-N (phenyl-$l^{2}-phosphanyl)benzene Chemical compound C=1C=CC=CC=1[P]C1=CC=CC=C1 JPJGNZQDELRZGE-UHFFFAOYSA-N 0.000 description 13
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 13
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 239000012362 glacial acetic acid Substances 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- CDUUKBXTEOFITR-BYPYZUCNSA-N 2-methyl-L-serine Chemical compound OC[C@@]([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-BYPYZUCNSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- OCSKCBIGEMSDIS-UHFFFAOYSA-N 1,3-dibromo-2-methylbenzene Chemical compound CC1=C(Br)C=CC=C1Br OCSKCBIGEMSDIS-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- MWYYNBYTVFKXSD-UHFFFAOYSA-N 3-bromo-4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1Br MWYYNBYTVFKXSD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101001091423 Agaricus bisporus Polyphenol oxidase 2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101000705994 Bombyx mori Phenoloxidase subunit 2 Proteins 0.000 description 2
- INRZXXPSUAFGCJ-ZSCHJXSPSA-N CC1=CC=C(C=C1)S(=O)(=O)O.COC([C@@](N)(CO)C)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O.COC([C@@](N)(CO)C)=O INRZXXPSUAFGCJ-ZSCHJXSPSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101000606124 Margaritifera margaritifera Tyrosinase-like protein 2 Proteins 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 101000773106 Pinctada maxima Tyrosinase-like protein Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- CDUUKBXTEOFITR-UHFFFAOYSA-N alpha-methylserine Natural products OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- MUMDGZCWRBIKDZ-UHFFFAOYSA-N (2,6-dibromophenyl)methanol Chemical compound OCC1=C(Br)C=CC=C1Br MUMDGZCWRBIKDZ-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- ZBEDLGKSWBORBS-UHFFFAOYSA-N 1,3,2-dioxaborolan-2-ol Chemical compound OB1OCCO1 ZBEDLGKSWBORBS-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- BLVSQFGBMQMIRS-UHFFFAOYSA-N 1-bromo-2-chloro-3-iodobenzene Chemical compound ClC1=C(Br)C=CC=C1I BLVSQFGBMQMIRS-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- DMARBQGIQKLIPM-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylbenzene Chemical compound CC1=C(Cl)C=CC=C1Br DMARBQGIQKLIPM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- QWTULQLVGNZMLF-UHFFFAOYSA-N 3-bromo-4-fluorophenol Chemical compound OC1=CC=C(F)C(Br)=C1 QWTULQLVGNZMLF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101001091417 Agaricus bisporus Polyphenol oxidase 1 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 101001125487 Bombyx mori Phenoloxidase subunit 1 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101000606125 Margaritifera margaritifera Tyrosinase-like protein 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 150000001482 benzyl phenyl ethers Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MCYYJHPHBOPLMH-UHFFFAOYSA-L disodium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane;hydrate Chemical class O.[Na+].[Na+].[O-]S([O-])(=O)=S MCYYJHPHBOPLMH-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- VKHHAZQVRNQDHW-YFKPBYRVSA-N methyl (2s)-2-amino-3-hydroxy-2-methylpropanoate Chemical compound COC(=O)[C@@](C)(N)CO VKHHAZQVRNQDHW-YFKPBYRVSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
- C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
- C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
- C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
- C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
- C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/21—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C47/22—Acryaldehyde; Methacryaldehyde
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/55—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本公开提供了一种联苯类化合物、其中间体、制备方法、药物组合物及应用。本公开的联苯类化合物对PD‑1和/或PD‑L1具有明显抑制作用,能够有效缓解或治疗癌症等相关疾病。
Description
技术领域
本公开涉及一种联苯类化合物、其中间体、制备方法、药物组合物及应用。
背景技术
PD-1(programmed death 1)程序性死亡受体1,是一种重要的免疫抑制分子。其为CD28超家族成员,最初是从凋亡的小鼠T细胞杂交瘤2B4.11克隆出来。以PD-1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植存活等均有重要的意义。其配体PD-L1也可作为靶点,相应的抗体也可以起到相同的作用。
PD-1/PD-L1发挥着负性免疫调节作用。当细胞表面的PD-1与PD-L1耦联后,可导致T细胞胞质区的免疫受体酪氨酸转换基序(Immunoreceptor Tyrosine-based Swithmotifs,ITSM)结构域的Tyr磷酸化,然后磷酸化的Tyr即可募集磷酸酶蛋白酪氨酸酶2和蛋白酪氨酸酶1,不仅可阻滞细胞外信号调节激酶的活化,还可阻断磷脂酰肌醇3-激酶(PI3K)和丝氨酸-苏氨酸蛋白激酶(Akt)的激活,最终抑制T淋巴细胞增殖和相关细胞因子的分泌。PD-1/PD-L1信号可抑制T细胞活化和增殖,与此同时,细胞因子白细胞介素2(IL2)、干扰素γ和IL-10的分泌也减少(Eur.J.Immunol.,2002,32(3),634-643.)。另外,PD-1/PD-L1信号对B细胞免疫功能也类似于T细胞,当PD-1与B细胞抗原受体发生交联后,PD-1细胞质区与含有蛋白酪氨酸酶2结合位点的酪氨酸酶发生作用,最终阻滞B细胞的活化。免疫负性调节分子PD-1/PD-L1在肿瘤免疫逃逸中的作用越来越引起人们的重视。大量研究证实,肿瘤微环境中的肿瘤细胞表面PD-L1增高,同时与活化的T细胞上的PD-1结合,传递负性调控信号,导致肿瘤抗原特异性T细胞的凋亡或免疫无能,从而抑制免疫反应,进而促使肿瘤细胞的逃逸。
目前已经上市的PD-1/PD-L1抗体抑制剂有BMS的Nivolumab(2014)、Merck的Lambrolizumab(2014)和罗氏的Atezolizumab(2016)。在研的PD-1/PD-L1抗体抑制剂有Cure Tech的Pidilizumab、GSK的AMP-224和阿斯利康MEDI-4736。以上这些都是生物大分子,而小分子PD-1/PD-L1抑制剂目前还处于前期研发阶段,Curis多肽类的PD-L1小分子抑制剂AC-170(WO2012168944,WO2015033299,WO2015033301,WO2015036927,WO2015044900)刚进入临床I期,BMS苄基苯基醚类的小分子PD-1/PD-L1抑制剂(WO2015034820,WO2015160641,WO2017066227,WO2018009505,WO2018044963,WO2018118848)还在临床前研究阶段,Incyte也做了一系列的小分子PD-1/PD-L1抑制剂(WO2017070089,WO2017087777,WO2017106634,WO2017112730,WO2017192961,WO2017205464,WO2017222976,WO2018013789,WO2018044783,WO2018119221,WO2018119224,WO2018119263,WO2018219266,WO2018119286)还处在临床前研究。相较于生物大分子,小分子化合物能够穿过细胞膜作用于细胞内靶点,所以应用范围广泛。其次,小分子经化学修饰后往往具有良好的生物利用度和依从性,有效避免消化肠道中酶类的分解失活。最后,在生产工艺、剂型设计和给药方式等多种层面,小分子的研究也颇为成熟。
目前现有技术中还未出现联苯类化合物作为小分子PD-1/PD-L1抑制剂成功上市的报道,该现状亟待解决。
发明内容
本公开的目的是为了提供一种与现有技术完全不同的联苯类化合物、其中间体、制备方法、药物组合物及应用。本公开的联苯类化合物对PD-1和/或PD-L1具有明显抑制作用,能够有效缓解或治疗癌症等相关疾病。
本公开提供了一种通式I所示的联苯类化合物、其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体或药物前体:
其中,
环A和环B独立地为芳环或杂芳环;
L1和L2独立地为化学键、炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-、取代或未取代的环烷基、取代或未取代的杂环烷基、取代或未取代的芳基或取代或未取代的杂芳基;
R5、R6、R7、R8、R9和R10分别独立地为氢、氘、卤素、氰基、或取代或未取代的烷基;
R1和R2独立地为氘、卤素、氰基或取代或未取代的烷基;
每个R3和每个R4独立地为氢、氘、羟基、-SR11、-NR12R13、卤素、氰基、取代或未取代的烷基、取代或未取代的烷氧基、-CONH2、-COR14、-COOR15或-OCOR16;R11、R12和R13独立地为氢、C1-C4烷基、取代的C1-C4烷基或-CORa,Ra为氢、羟基、C1-C4烷基或C1-C4烷氧基;
R14、R15和R16独立地为氢、C1-C4烷基或取代的C1-C4烷基;
R11、R12、R13、R14、R15和R16中,所述取代的C1-C4烷基中的取代是指被C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代;
L1和L2中所述的取代的环烷基、所述的取代的杂环烷基、所述的取代的芳基、所述的取代的杂芳基、R1和R2中所述的取代的烷基、每个R3和每个R4中所述的取代的烷基或所述的取代的烷氧基中的取代基选自卤素、氰基、C1-C4烷基、羟基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基、C1-C4烷氧基、C1-C4羧基、C1-C4酯基和C1-C4酰胺基中的一个或多个;/>中,R17和R18独立地为氢、取代或未取代的C1-C4烷基、取代或未取代的C6-C14芳基、取代或未取代的C3-C6环烷基、或取代或未取代的C1-C4烷氧基;或者R17、R18和与它们相连接的氮原子一起形成一个取代或未取代的5-7元碳杂环;所述碳杂环中,杂原子为N,或N和O,杂原子数为1-4个;每个R17和每个R18相同或不同;
R17和R18中所述的取代的C1-C4烷基、所述的取代的C6-C14芳基、所述的取代的C3-C6环烷基、所述取代的C1-C4烷氧基和所述的取代的5-7元碳杂环中的取代基选自卤素、氰基、C1-C4烷基、取代的C1-C4烷基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基、羟基、C1-C4烷氧基、C1-C4羧基、C1-C4酯基和C1-C4酰胺基中的一个或多个;
R17和R18中,当所述的取代的C1-C4烷基、所述的取代的C6-C14芳基、所述的取代的C3-C6环烷基、所述取代的C1-C4烷氧基和所述的取代的5-7元碳杂环中的取代基为取代的C1-C4烷基时,取代基中,所述的取代的C1-C4烷基中的取代基选自卤素、氰基、C1-C4烷基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基、羟基、C1-C4烷氧基、C1-C4羧基、C1-C4酯基和C1-C4酰胺基中的一个或多个;/>中,Ra1和Rb1独立地为氢、C1-C4的烷基或/>Ra11为C1-C4的烷基;
上述所有C1-C10杂芳基是指杂原子选自N、O和S,杂原子数为1-4个的C1-C10杂芳基;
上述所有取代的C6-C14芳基和取代的C1-C10杂芳基中的取代基选自氰基、卤素、羟基、C1-C4烷基和C1-C4烷氧基中的一个或多个;
当取代基为多个时,所述的取代基相同或不同;
m为1、2或3;
n为1、2或3。
本公开中,所有术语芳环是指任何稳定的在各环中可高达7个原子的单环或者双环碳环,其中至少一个环是芳香环。所有术语芳环优选C6-C20芳环,更优选C6-C14芳环,最优选C6-C10芳环。芳环的实例包括但不限于苯、萘、四氢萘、2,3-二氢化茚、联苯、菲、蒽或苊。
本公开中,所有术语杂芳环是指表示各环中可高达7个原子的稳定单环或者二环,其中至少一个环是芳香环并且含有1-4个选自O、N、和S的杂原子。本公开中“杂芳环”优选是指杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C10的杂芳环,进一步优选杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C8的杂芳环,更优选杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C6的杂芳环。杂芳环的实例包括但不限于:吖啶、咔唑、噌啉、咔啉、喹喔啉、咪唑、吡唑、吡咯、吲哚、二氢吲哚、苯并***、苯并咪唑、呋喃、噻吩、异噻唑、苯并噻吩、二氢苯并噻吩、苯并呋喃、异苯并呋喃、苯并噁唑、苯并呋咱、苯并吡唑、喹啉、异氮杂茚、异喹啉、噁唑、噁二唑、异噁唑、吲哚、吡嗪、吡啶并吡啶、四唑并吡啶、哒嗪、吡啶、萘嘧啶、嘧啶、吡咯、四唑、噻二唑、噻唑、噻吩、***、喹唑啉、四氢喹啉、二氢苯并咪唑、二氢苯并呋喃、二氢苯并噁唑和二氢喹啉。
本公开中,所有术语环烷基优选C3-C20环烷基,更优选C3-C10环烷基,最优选C3-C6环烷基。环烷基的实例包括但不限于:环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环癸烷和环十二烷基和环己烯基。
本公开中,所有术语杂环烷基是指杂原子选自O、N和S,杂原子数为1、2、3或4个的C2-C10的非芳香环。本公开中,杂环烷基优选杂原子选自O、N和S,杂原子数为1、2、3或4个的C2-C8的杂环烷基,进一步优选杂原子选自O、N和S,杂原子数为1、2、3或4个的C2-C6的杂环烷基。杂环烷基的实例包括但不限于:四氢吡喃基、氮杂环丁烷基、1,4-二噁烷基、哌嗪基、哌啶基、吡咯烷基、吗啉基、硫代吗啉基、二氢呋喃基、二氢咪唑基、二氢吲哚基、二氢异噁唑基、二氢异噻唑基、二氢噁二唑基、二氢噁唑基、二氢吡嗪基、二氢吡唑基、二氢吡啶基、二氢嘧啶基、二氢吡咯基、二氢喹啉基、二氢四唑基、二氢噻二唑基、二氢噻唑基、二氢噻吩基、二氢***基、二氢氮杂环丁烷基、亚甲基二氧基苯甲酰基、四氢呋喃基、四氢噻吩基及其N-氧化物。
本公开中,所有术语芳基优选C6-C20芳基,更优选C6-C14芳基,最优选C6-C10芳基。芳基的实例包括但不限于苯基、萘基、四氢萘基、2,3-二氢化茚基、联苯基、菲基、蒽基和苊基(acenaphthyl)。
本公开中,所有术语杂芳基优选杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C10的杂芳基,进一步优选杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C8的杂芳基,更优选杂原子选自O、N和S,杂原子个数为1、2、3或4个的C1-C6的杂芳基。杂芳基的实例包括但不限于苯并咪唑基、苯并呋喃基、苯并呋咱基、苯并吡唑基、苯并***基、苯并噻吩基、苯并噁唑基、咔唑基、咔啉基、噌啉基、呋喃基、咪唑基、二氢吲哚基、吲哚基、吲唑基、异苯并呋喃基、异氮杂茚基、异喹啉基、异噻唑基、异噁唑基、萘嘧啶基、噁二唑基、噁唑基、噁唑啉、异噁唑啉、氧环丁基、吡喃基、吡嗪基、吡唑基、哒嗪基、吡啶并吡啶基、哒嗪基、吡啶基、嘧啶基、吡咯基、喹唑啉基、喹啉基、喹喔啉基、四唑基、四唑并吡啶基、噻二唑基、噻唑基、噻吩基和***基。
本公开中,所有术语卤素优选氟、氯、溴或碘。
本公开中,所有术语烷基包括1-20个碳原子的支链和直链的饱和脂族烃基,优选1-10个碳原子,更优选1-8个碳原子。烷基的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、戊基、己基、庚基、辛基、壬基、癸基、4,4-二甲基戊基、2,2,4-三甲基戊基、十一烷基、十二烷基,及它们的各种异构体。本公开中烷基优选C1-C4烷基,更优选甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
本公开中,所有术语烷氧基表示通过氧桥连接的具有所述碳原子数目的环状或者非环状烷基。由此,烷氧基包含以上烷基和环烷基的定义。本公开中烷氧基优选C1-C4烷氧基,更优选甲氧基、乙氧基、正丙氧基、异丙氧基或叔丁氧基。
本公开中,所有术语5-7元碳杂环是指杂原子选自O、N和S,杂原子数为1、2、3或4个,碳原子数为1、2、3、4、5或6个的5-7元碳杂环。所述的5-7元碳杂环中环原子为5、6或7个。本公开中,所述的5-7元碳杂环包括但不限于:氮杂环丁烷基、哌嗪基、哌啶基、吡咯烷基、吗啉基、硫代吗啉基、二氢咪唑基、二氢吲哚基、二氢异噁唑基、二氢异噻唑基、二氢噁二唑基、二氢噁唑基、二氢吡嗪基、二氢吡唑基、二氢吡啶基、二氢嘧啶基、二氢吡咯基、二氢喹啉基、二氢四唑基、二氢噻二唑基、二氢噻唑基、二氢***基和二氢氮杂环丁烷基。
在一优选实施方案中,L1为炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-、取代或未取代的环烷基、取代或未取代的杂环烷基、取代或未取代的芳基、或取代或未取代的杂芳基,优选炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-,更优选-C(R5)=C(R6)-,最优选-CH=CH-。
在一优选实施方案中,L2为炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-、取代或未取代的环烷基、取代或未取代的杂环烷基、取代或未取代的芳基、或取代或未取代的杂芳基,优选炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-,更优选-C(R5)=C(R6)-,最优选-CH=CH-。
在一优选实施方案中,L2不存在。
在一优选实施方案中,R5、R6、R7、R8、R9和R10分别独立地为氢或氘。
在一优选实施方案中,R1为卤素,例如F、Cl、Br或I。
在一优选实施方案中,R1为氰基。
在一优选实施方案中,R1为烷基,优选C1-C4烷基,更优选甲基。
在一优选实施方案中,R1为取代的烷基。所述的取代的烷基中的取代基优选卤素或羟基。R1优选被卤素取代的烷基。,所述的被卤素取代的烷基优选被F、Cl、Br和I中的一个或多个取代的C1-C4烷基,更优选-CH2F、-CHF2或-CF3。
在一优选实施方案中,R2为氘。
在一优选实施方案中,R2为卤素,例如F、Cl、Br或I。
在一优选实施方案中,R2为氰基。
在一优选实施方案中,R2为烷基,优选C1-C4烷基,更优选甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
在一优选实施方案中,R2为取代的烷基,优选取代的C1-C4烷基。所述的取代的烷基中的取代基优选卤素、氰基、C1-C4烷基、羟基、C1-C4烷氧基、C1-C4羧基、C1-C4酯基和C1-C4酰胺基中的一个或多个,当取代基为多个时,所述的取代基相同或不同。所述的被卤素取代的烷基优选被F、Cl、Br和I中的一个或多个取代的C1-C4烷基,更优选-CH2F、-CHF2或-CF3。
在一优选实施方案中,R2在苯环1位。
在一优选实施方案中,R3和R4优选独立地为氘、卤素、氰基、-SR11、-NR12R13、取代或未取代的烷基、或取代或未取代的烷氧基。
在一优选实施方案中,R3和R4优选独立地为氘、卤素、氰基、-SR11、取代或未取代的烷基、或取代或未取代的烷氧基。
在一优选实施方案中,R3和R4优选-SR11,R11为取代的C1-C4烷基。
在一优选实施方案中,R3和R4优选卤素。
在一优选实施方案中,R3和R4优选取代或未取代的烷基。所述的取代的烷基中的取代基优选被卤素、氰基、羟基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基、C1-C4烷氧基和C1-C4羧基中的一个或多个取代。当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,R3和R4优选取代的烷基。所述的取代的烷基中的取代基优选被卤素、取代的C6-C14芳基和取代的C1-C10杂芳基中的一个或多个取代。当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,R3和R4优选被卤素取代的烷基。所述的被卤素取代的烷基优选被F、Cl、Br和I中的一个或多个取代的C1-C4烷基,优选-CF3。
在一优选实施方案中,R3和R4优选被取代的烷基。所述的被/>取代的烷基优选被/>取代的C1-C4的烷基。所述的被/>取代的C1-C4的烷基优选/> 其中,R17和R18一个为H,另一个为被羟基和/或羧基取代的烷基。
在一优选实施方式中,R17和R18一个为H,另一个为被C1-C4烷氧基、羟基和羧基中的一个或多个取代的烷基。
在一优选实施方案中,当R3和R4为被取代的烷基时,所述的被/>取代的烷基优选/>
在一优选实施方案中,R3或R4优选被取代的C6-C14芳基取代的烷基,更优选
在一优选实施方案中,R3或R4优选被取代的C1-C10杂芳基取代的烷基,更优选
在一优选实施方式中,当R3为取代或未取代的烷基(被取代的烷基)时,R3位于环A上与L1相连的原子的间位或对位。
在一优选实施方式中,当R4为取代或未取代的烷基(例如被取代的烷基)时,R4位于环B上与L2相连的原子的间位或对位。
在一优选实施方式中,当R3为取代或未取代的烷基(例如被取代的烷基)时,环A上还可有0、1或2个取代基。当还可有1个取代基时,该取代基位于取代或未取代的烷基(例如被/>取代的烷基)的对位、间位或邻位。
在一优选实施方式中,当R4为取代或未取代的烷基(例如被取代的烷基)时,环B上还可有0、1或2个取代基。当还可有1个取代基时,该取代基位于取代或未取代的烷基(例如被/>取代的烷基)的对位、间位或邻位。
在一优选实施方案中,R3和R4为取代或未取代的烷氧基。所述的取代的烷氧基中的取代基优选被卤素、氰基、羟基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代。当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,R3和R4为取代或未取代的烷氧基。所述的取代的烷氧基中的取代基优选被卤素、氰基、羟基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基和C1-C4烷氧基中的一个或多个取代。当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,R3和R4为取代的烷氧基,所述的取代的烷氧基中的取代基优选被C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代,当取代基为多个时,所述的取代基相同或不同。所述的取代的烷氧基优选
在一优选实施方案中,R3和R4优选取代的烷氧基,所述的取代的烷氧基中的取代基优选被C1-C4烷氧基取代。所述的取代的烷氧基优选
在一优选实施方式中,当R3为取代或未取代的烷氧基时,R3位于环A上与L1相连的原子的邻位或间位。
在一优选实施方式中,当R4为取代或未取代的烷氧基时,R4位于环B上与L2相连的原子的邻位或间位。
在一优选实施方式中,基团优选/>其中,R1和R2的定义均同前所述。
在一优选实施方式中,基团优选/>
在一优选实施方式中,和/>独立地为/>和/>其中M1和N1为被/>取代的烷基,或者M1和N1其中一个为被/>取代的烷基,另一个为取代的烷氧基;其中M1和N1中,被/>取代的烷基的定义和取代的烷氧基的定义,均同前R3或R4中相应的基团;R17、R18、R3和R4的定义均同前所述,n1和m1独立地为0、1或2。
优选地,M1和N1为或者M1和N1其中一个为/>另一个为被C1-C4烷氧基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代的烷氧基;R3和R4优选氢、卤素、烷基、被卤素取代的烷基、烷氧基或取代的烷氧基,所述的取代的烷氧基中的取代基优选被C1-C4烷氧基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代;R17和R18的定义均同前所述。
更优选地,M1和N1为或者M1和N1其中一个为/>另一个为被C1-C4烷氧基取代的烷氧基;R3和R4优选卤素、烷基、被卤素取代的烷基、烷氧基或被C1-C4烷氧基取代的烷氧基;R17和R18的定义均同前所述。
在一优选实施方式中,优选/> 其中N1、R17和R18的定义均同前所述。
在一优选实施方式中,优选/> 其中M1、R17和R18的定义均同前所述。
在一优选实施方式中,和/>独立地优选/>/>
/>
在一优选实施方案中,优选/>/>
在一优选实施方式中,优选/>
在一优选实施方式中,和/>独立地优选
在一优选实施方案中,
L1为炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-,
L2为炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-或不存在,
R5、R6、R7、R8、R9和R10分别独立地为氢或氘,
R1为卤素、或取代或未取代的烷基,
R2为卤素、或取代或未取代的烷基,和
R3和R4独立地为氘、卤素、氰基、-SR11、-NR12R13、取代或未取代的烷基、或取代或未取代的烷氧基。
在一优选实施方案中,
L1为炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-,
L2为炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-或不存在,
R5、R6、R7、R8、R9和R10分别独立地为氢或氘,
R1为卤素、或取代或未取代的烷基,
R2为卤素、或取代或未取代的烷基,和
R3和R4独立地为卤素、-SR11、取代或未取代的烷基、或取代或未取代的烷氧基;R11为取代的C1-C4烷基;所述的取代的烷基中的取代基为被卤素、氰基、羟基、C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基、取代的C1-C10杂芳基、C1-C4烷氧基和C1-C4羧基中的一个或多个取代;所述的取代的烷氧基中的取代基为被卤素、氰基、羟基、/>C6-C14芳基、取代的C6-C14芳基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代;当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,
L1为炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-,
L2为炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-或不存在,
R5、R6、R7、R8、R9和R10分别独立地为氢或氘;
R1为卤素、取代或未取代的烷基;
R2为卤素或烷基,
R3和R4独立地为卤素、-SR11、取代或未取代的烷基、或取代或未取代的烷氧基;R11为取代的C1-C4烷基;所述的取代的烷基中的取代基为被卤素、取代的C6-C14芳基和取代的C1-C10杂芳基中的一个或多个取代;所述的取代的烷氧基中的取代基优选被C1-C4烷氧基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代;当取代基为多个时,所述的取代基相同或不同。
在一优选实施方案中,
L1为-C(R5)=C(R6)-(优选-CH=CH-),
L2为-C(R5)=C(R6)-或不存在(优选-CH=CH-),
R5和R6独立地为氢或氘,
R1为卤素、烷基(优选C1-C4烷基,更优选甲基)、或被卤素取代的烷基,
R2为卤素或烷基(优选C1-C4烷基,更优选甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基),
R3和R4独立地为卤素、-SR11、取代或未取代的烷基、或取代或未取代的烷氧基;R11为取代的C1-C4烷基;所述的取代的烷基中的取代基优选被卤素、取代的C6-C14芳基和取代的C1-C10杂芳基中的一个或多个取代(进一步地R3和R4定义如下:(1)R3和R4优选-SR11,R11为取代的C1-C4烷基;(2)R3和R4优选被卤素取代的烷基;所述的被卤素取代的烷基优选被F、Cl、Br和I中的一个或多个取代的C1-C4烷基,优选-CF3;
(3)R3和R4优选被取代的烷基;所述的被/>取代的烷基优选被/>取代的C1-C4的烷基;所述的被/>取代的C1-C4的烷基优选/>其中,R17和R18一个为H,另一个为被C1-C4烷氧基、羟基和羧基中的一个或多个取代的烷基;当R3和R4为被/>取代的烷基时,所述的被/>取代的烷基优选/>/>
(4)R3和R4优选被取代的C6-C14芳基取代的烷基,更优选/>(5)R3和R4优选被取代的C1-C10杂芳基取代的烷基,更优选/>(6)R3和R4优选取代的烷氧基,所述的取代的烷氧基中的取代基优选被C1-C4烷氧基、C1-C10杂芳基和取代的C1-C10杂芳基中的一个或多个取代,所述的取代的烷氧基优选/>)。
本公开中所述的通式I所示的联苯类化合物优选选自下列任一化合物:
/>
在一优选实施方案中,所述的通式I所示的联苯类化合物优选通式I-A或II所示的联苯类化合物:
/>
其中,环A、环B、L1、L2、R1、R2、R3、R4、M1、N1、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2。
本公开中,通式II所示的联苯类化合物中,环A中的和环B中的/>可相同或也可不同。
本公开还提供了一种所述的通式I-A或II所示的联苯类化合物的制备方法,
通式I-A所示的化合物中,当M1和N1中含有-NH-或-COOH时,其采用下列方法制备:所述方法包括下列步骤:将通式II-F所示的化合物进行如下所示脱保护反应,制得所述的通式I-A所示的联苯类化合物,
其中环A、环B、L1、L2、R1、R2、R3、R4、M1和N1的定义均同前所述,n1为0、1或2,m1为0、1或2,RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1与N1相同;或者,RIIF和M1相同,RIIF1为N1对应的含有氨基或羧基保护基的基团;或者RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1为N1对应的含有氨基或羧基保护基的基团;
通式II所示的联苯类化合物的制备方法采用下列任一方法:
(1)方法一包括下列步骤:将通式II-A所示的化合物和化合物II-A1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-A1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2;在此方法中,环A和环B中的相同;
(2)方法二包括下列步骤:将通式II-B所示的化合物和化合物II-B1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-B1结构如下:或其酸式盐,/>
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2,M为卤素;在此方法中,环A和环B中的相同;
(3)方法三包括下列步骤:将通式II-C所示的化合物和化合物II-C1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-C1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2;RIIC和RIIC1其中一个为另一个为/>在此方法中,环A和环B中的/>相同或不同;
(4)方法四包括下列步骤:将通式II-D所示的化合物和化合物II-D1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-D1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2,RIID和RIID1其中一个为另一个为卤素,在此方法中,环A和环B中的/>相同或不同;
(5)方法五包括下列步骤:将通式II-E所示的化合物进行如下所示脱保护反应,制得所述的通式II所示的联苯类化合物,通式II所示的化合物中R17或R18中含有羧基;
其中环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2,RIIE和RIIE1为每个R17’和每个R18’相同或不同,且至少有一个有羧基保护基,不含羧基保护基的R17’和R18’分别与通式II中对应的R17和R18相同;此方法中,环A和环B中的相同或不同。
本公开还提供了通式II-A、II-B、II-C、II-D、II-E和II-F所示的化合物:
环A、环B、L1、L2、R1、R2、R3、R4、M1、N1、R17和R18的定义均同前所述,n1为0、1或2,m1为0、1或2;M为卤素,RIIC和RIIC1其中一个为另一个为/>RIID和RIID1其中一个为另一个为卤素,RIIE和RIIE1为/>每个R17’和每个R18’相同或不同,且至少有一个有羧基保护基,不含羧基保护基的R17’和R18’分别与通式II中对应的R17和R18相同;RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1与N1相同;或者,RIIF和M1相同,RIIF1为N1对应的含有氨基或羧基保护基的基团;或者RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1为N1对应的含有氨基或羧基保护基的基团。
本公开还提供了如下所示的化合物:
/>
本公开还提供了所述的通式I所示的联苯类化合物、其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体或药物前体在制备PD-1抑制剂和/或PD-L1抑制剂中的应用。
本公开还提供了所述的通式I所示的联苯类化合物、其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体和药物前体中的一种或多种在制备用于预防、缓解或治疗癌症、感染、自身免疫性疾病或其相关疾病的药物中的应用。
所述癌症优选肺癌、食管癌、胃癌、大肠癌、肝癌、鼻咽癌、脑肿瘤、乳腺癌、***、血癌和骨癌中的一种或多种。
本公开还提供了一种药物组合物,其包括治疗和/或预防有效量的所述的通式I所示的联苯类化合物、其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体或药物前体,及药学上可接受载体和/或稀释剂。
本公开中,根据治疗目的,可将药物组合物制成各种类型的给药单位剂型,如片剂、丸剂、粉剂、液体、悬浮液、乳液、颗粒剂、胶囊、栓剂和针剂(溶液及悬浮液)等,优选液体、悬浮液、乳液、栓剂和针剂(溶液及悬浮液)等。
为了使片剂形式的药物组合物成形,可使用本领域任何已知并广泛使用的赋形剂。例如,载体,如乳糖、白糖、氯化钠、葡萄糖、尿素、淀粉、碳酸钙、高岭土、结晶纤维素和硅酸等;粘合剂,如水、乙醇、丙醇、普通糖浆、葡萄糖溶液、淀粉溶液、明胶溶液,羧甲基纤维素、紫胶、甲基纤维素和磷酸钾、聚乙烯吡咯烷酮等;崩解剂,如干淀粉、藻酸钠、琼脂粉和海带粉,碳酸氢钠、碳酸钙、聚乙烯脱水山梨醇的脂肪酸酯、十二烷基硫酸钠、硬脂酸单甘酯、淀粉和乳糖等;崩解抑制剂,如白糖、甘油三硬脂酸酯、椰子油和氢化油;吸附促进剂,如季胺碱和十二烷基硫酸钠等;润湿剂,如甘油、淀粉等;吸附剂,如淀粉、乳糖、高岭土、膨润土和胶体硅酸等;以及润滑剂,如纯净的滑石,硬脂酸盐、硼酸粉和聚乙二醇等。还可以根据需要选用通常的涂渍材料制成糖衣片剂、涂明胶膜片剂、肠衣片剂、涂膜片剂、双层膜片剂及多层片剂。
为了使丸剂形式的药物组合物成形,可使用本领域任何已知的并广泛使用的赋形剂,例如,载体,如乳糖,淀粉,椰子油,硬化植物油,高岭土和滑石粉等;粘合剂,如***树胶粉,黄蓍胶粉,明胶和乙醇等;崩解剂,如琼脂和海带粉等。
为了使栓剂形式的药物组合物成形,可使用本领域任何已知并广泛使用的赋性剂,例如,聚乙二醇,椰子油,高级醇,高级醇的酯,明胶和半合成的甘油酯等。
为了制备针剂形式的药物组合物,可将溶液或悬浮液消毒后(最好加入适量的氯化钠,葡萄糖或甘油等),制成与血液等渗压的针剂。在制备针剂时,也可使用本领域内任何常用的载体。例如,水,乙醇,丙二醇,乙氧基化的异硬脂醇,聚氧基化的异硬脂醇和聚乙烯脱水山梨醇的脂肪酸酯等。此外,还可加入通常的溶解剂、缓冲剂和止痛剂等。
所述药物组合物中,所述稀释剂可为本领域中常规的稀释剂。
所述药物组合物可以是口服的形式,也可以是无菌注射水溶液形式,可按照本领域任何已知制备药用组合物的方法制备口服或注射组合物。
除非另有说明,在本公开说明书和权利要求书中出现的以下所有术语具有下述含义:
所有术语环烷基(包括单独使用及包含在其它基团中时)包含饱和或部分不饱和(包含1或2个双键)的包含1-3个环的环状碳氢基团,其包括单环烷基、双环烷基以及三环烷基。
所有术语烷氧基表示通过氧桥连接的具有所述碳原子数目的环状或者非环状烷基。由此,烷氧基包含以上烷基和环烷基的定义。
所有术语烯基是指含有指定数目碳原子和至少一个碳碳双键的直链、支链或者环状非芳香烃基。优选存在一个碳碳双键,并且可以存在高达四个非芳香碳碳双键。烯基优选C2-12烯基,进一步优选C2-6烯基。由此,C2-12烯基是指具有2-12个碳原子的烯基。C2-6烯基是指具有2-6个碳原子的烯基,包括乙烯基、丙烯基、丁烯基、2-甲基丁烯基和环己烯基。烯基的直链、支链或者环部分可以含有双键,并且如果表明为取代烯基,那么可以被取代。
所有术语炔基是指含有指定数目碳原子和至少一个碳碳三键的直链、支链或者环状烃基。其中可以存在高达三个碳碳三键。炔基优选为C2-12炔基,进一步优选为C2-6炔基。由此,C2-12炔基是指具有2-12个碳原子的炔基。C2-6炔基是指具有2-6个碳原子的炔基,包括乙炔基、丙炔基、丁炔基和3-甲基丁炔基等等。
所有术语羟基表示
所有术语氨基表示
所有术语氰基表示-CN。
所有术语羧基表示-COOH,其中C1-C4羧基是指-(CH2)nCOOH,n为0、1、2或3。所有术语C1-C4羧基优选
所有术语酯基表示-COO-,其中C1-C4酯基是指-COORx,Rx为C1-C4烷基。
所有术语酰胺基表示“-CONRx1Rx2”或“-NRx3CORx4”,Rx1、Rx2、Rx3和Rx4独立地为H或C1-C4烷基。
所有术语杂芳环还应当理解为包括任何含氮杂芳环的N-氧化物衍生物。在其中杂芳基取代基是二环取代基并且一个环是非芳香环或者不包含杂原子的情况下,可以理解,连接分别通过芳环或者通过包含环的杂原子进行。
所有术语治疗有效量是指在给予受试者时足以有效治疗本文所述的疾病或病症的化合物的量。虽然构成“治疗有效量”的化合物的量将根据化合物、病症及其严重度、以及欲治疗受试者的年龄而变化,但可由本领域技术人员以常规方式确定。
当提到具体盐、药物组合物、组合物、辅料等“药学上可接受的”时,是指该盐、药物组合物、组合物、辅料等一般无毒、安全,并且适合于受试者使用,优选哺乳动物受试者,更优选为人受试者。
所有术语药学上可接受的盐指本公开化合物的药学上可接受的有机或无机盐。示例性盐包括但不限于:硫酸盐、柠檬酸盐、乙酸盐、草酸盐、氯化物、溴化物、碘化物、硝酸盐、硫酸氢盐、磷酸盐、酸式磷酸盐、异烟酸盐、乳酸盐、水杨酸盐、酸式柠檬酸盐、酒石酸盐、油酸盐、单宁酸盐、泛酸盐、酒石酸氢盐、抗坏血酸盐、琥珀酸盐、马来酸盐、龙胆酸盐(gentisinate)、富马酸盐、葡糖酸盐、葡糖醛酸盐、糖酸盐、甲酸盐、苯甲酸盐、谷氨酸盐、甲烷磺酸盐、乙烷磺酸盐、苯磺酸盐、对甲苯磺酸盐和双羟萘酸盐(即1-1-亚甲基-双(2-羟基-3-萘甲酸盐))。
所有术语药物前体是指包含生物反应官能团的化合物的衍生物,使得在生物条件下(体外或体内),生物反应官能团可从化合物上裂解或以其他方式发生反应以提供所述化合物。通常,药物前体无活性,或者至少比化合物本身活性低,使得直到将所述化合物从生物反应官能团上裂解后才能发挥其活性。生物反应官能团可在生物条件下水解或氧化以提供所述化合物。例如,药物前体可包含可生物水解的基团。可生物水解的基团实例包括但不限于可生物水解的磷酸盐、可生物水解的酯、可生物水解的酰胺、可生物水解的碳酸酯、可生物水解的氨基甲酸酯和可生物水解的酰脲。
本公开的化合物可以含有一个或多个不对称中心(“立体异构体”)。如本文所用,所有术语“立体异构体”是指顺式-和反式-异构体、R-和S-对映体以及非对映体。这些立体异构体可以通过不对称合成法或手性分离法(例如,分离、结晶、薄层色谱法、柱色谱法、气相色谱法、高效液相色谱法)制备。这些立体异构体也可由对映体或外消旋物的混合物与适当的手性化合物反应的非对映体衍生,然后通过结晶或任何其它合适的常规方法得到。
所有术语受试者是指根据本公开的实施例,即将或已经接受了该化合物或药物组合物给药的任何动物,哺乳动物为优,人类最优。如本文所用所有术语“哺乳动物”包括任何哺乳动物。哺乳动物的实例包括但不限于牛、马、羊、猪、猫、狗、小鼠、大鼠、家兔、豚鼠、猴、人等,以人类为最优。
在某些实施例中,治疗或正在治疗是指疾病或病症或其至少一个可辨别症状的改善、预防或逆转。在另一些实施例中,治疗或正在治疗是指正在治疗的疾病或病症的至少一个可测量身体参数的改善、预防或逆转,可能并未在哺乳动物中识别所述疾病或病症。然而在另一个实施例中,治疗或正在治疗是指减慢疾病或病症的进展,或者是身体上的,例如可辨别症状的稳定,或生理学上的,例如,身体参数的稳定,或两者兼而有之。在另一些实施例中,治疗或正在治疗是指延迟疾病或病症的发作。
在某些实施例中,本公开的化合物可作为预防措施给药。如本文所用,“预防”或“正在预防”是指降低获得给定疾病或病症的风险。在实施例的优选模式中,将指定化合物作为预防措施给予受试者,例如有癌症或自身免疫性疾病家族病史或倾向的受试者。
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本公开各较佳实例。
本公开所用试剂和原料均市售可得。
本公开的积极进步效果在于:本公开的联苯类化合物对PD-1和PD-L1具有明显抑制作用,能够有效缓解或治疗癌症等相关疾病。
具体实施方式
下面通过实施例的方式进一步说明本公开,但并不因此将本公开限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
下述实施例中,室温是指10℃-30℃;回流是指溶剂回流温度;过夜是指8-24小时,优选12-18小时。
化合物的结构由核磁共振(NMR)或质谱(MS)来确定,核磁共振谱是通过BrukerAvance-500仪器获得,氘代二甲亚砜,氘代氯仿和氘代甲醇等为溶剂,四甲基硅烷(TMS)为内标。质谱是由液相色谱-质谱(LC-MS)联用仪Agilent Technologies 6110获得,采用ESI离子源。
微波反应是在美国CEM公司生产的Explorer全自动微波合成仪中进行,磁控管频率为2450MHz,连续微波输出功率为300W。
高效液相制备所用的仪器是Gilson 281,所用的制备柱是Shimadazu Shim-Pack,PRC-ODS,20x250 mm,15μm。
实施例1
2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-羟乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-甲基苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-1-乙醇1
化合物1-f的合成
在室温条件下,往2-溴-6-氯甲苯(15.67g,76.26mmol)和乙烯基硼酸频哪醇酯(14.30g,91.51mmol)的甲苯(300mL)溶液中加入二(三叔丁基膦)钯(2.73g,5.34mmol)和三乙胺(61.74g,610.08mmol),将反应液加热至80℃,在氮气条件下搅拌反应过夜。反应结束后,加入乙酸乙酯稀释(100mL),用水(100mL)和饱和食盐水(100mL)洗涤。所得有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得化合物1-f(10.5g,产率:49.4%)。
1H NMR(500MHz,CDCl3):δ7.65-7.62(d,J=18.5Hz,1H),7.42-7.41(d,J=7.5Hz,1H),7.31-7.30(d,J=7.5Hz,1H),7.12-7.09(t,1H),6.06-6.02(d,J=18.0Hz,1H),2.45(s,3H),1.32(s,12H).
化合物1-e的合成
在室温条件下,往3-溴-4-三氟甲基苯甲醛(4.16g,16.45mmol)和化合物1-f(5.5g,19.74mmol)的1,4-二氧六环(40mL)和水(2mL)的混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(1.423g,1.645mmol)和碳酸钠(4.36g,41.13mmol),将反应液加热至80℃,在氮气条件下搅拌16小时。反应结束后,加入乙酸乙酯(50mL)稀释,依次用水(50mL)和饱和食盐水(50mL)洗涤。所得有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=40:1)得到化合物1-e(4.16g,产率:78%)
1H NMR(500MHz,CDCl3):δ10.15(s,1H),8.25(s,1H),7.87(s,2H),7.47-7.40(m,2H),7.37-7.36(d,J=7.0Hz,1H),7.32-7.29(m,1H),7.20-7.17(m,1H),2.50(s,3H).
化合物1-d的合成
向100毫升反应瓶中加入化合物1-e(3.24g,10mmol),联硼酸频哪醇酯(3.05g,12mmol),三(二亚苄基丙酮)二钯(458mg,0.5mmol),2-二环己基磷-2',4',6'-三异丙基联苯(952mg,2.0mmol),醋酸钾(3.0g,112mmol)以及甲苯(80mL)。混合物于90℃,氮气保护下反应16小时。冷却至室温,过滤,滤液减压浓缩,所得的剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=25:1)得到化合物1-d(3.06g,产率:82%)。
1H NMR(500MHz,CDCl3):δ10.15(s,1H),8.28(s,1H),7.85(s,2H),7.73-7.76(m,1H),7.62(d,J=7.5Hz,1H),7.50(d,J=18Hz,1H),7.26-7.28(m,1H),7.23(d,J=7.5Hz,1H),2.65(s,3H),1.37(s,12H).
化合物1-c的合成
室温下,往化合物1-d(416.24mg,1.0mmol)的四氢呋喃(20mL)溶液中加入双氧水(30%,1mL),反应液在常温条件下搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用饱和硫代硫酸钠水(20mL)洗涤两次,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,所得的剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得化合物1-c(220mg,产率:71.9%)。
1H NMR(400MHz,CDCl3):δ10.17(s,1H),8.29(s,1H),7.89(s,2H),7.48-7.45(d,J=16.0Hz,1H),7.37-7.33(m,1H),7.23-7.21(d,J=7.5Hz,1H),7.16-7.13(t,1H),6.82-6.80(d,J=8.0Hz,1H),4.90(s,1H),2.38(s,3H).
化合物1-b的合成
室温下,往化合物1-c(529mg,1.73mmol)和苯基双(三氟甲烷磺酰)亚胺(618mg,1.73mmol)的丙酮(20mL)溶液中加入碳酸钾(358mg,2.59mmol),反应液在常温条件下搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用饱和硫代硫酸钠水溶液(20mL)洗涤两次,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,所得的剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=40:1~20:1)得化合物1-b(391mg,产率:51.7%)。
1H NMR(400MHz,CDCl3):δ10.08(s,1H),8.18(s,1H),7.85-7.81(m,2H),7.54-7.52(d,J=7.5Hz,1H),7.30(s,2H),7.28-7.24(m,1H),7.19-7.18(m,1H),2.39(t,3H).
化合物1-a的合成
氮气保护下,往化合物1-b(391mg,0.892mmol)和化合物1-d(445.4mg,1.070mmol)的1,4-二氧六环(20mL)和水(1mL)混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(77.2mg,0.0892mmol)和碳酸钠(236.4mg,2.23mmol)。反应液加热至80℃,并搅拌16小时。反应液冷却至室温,加乙酸乙酯溶液(20mL)稀释后,用水(20mL)洗涤三次,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶薄层层析制备板纯化(石油醚:乙酸乙酯=10:1)得化合物1-a(116mg,产率:22.5%)。
1H NMR(400MHz,CDCl3):δ10.07(s,2H),8.22(s,2H),7.80(s,4H),7.57-7.55(d,J=7.5Hz,2H),7.46-7.43(d,J=15.5Hz,2H),7.36-7.31(m,2H),7.26-7.21(m,2H),7.08-7.07(d,J=7.0Hz,2H),2.11(s,6H).
化合物1的合成
室温下,往化合物1-a(100mg,0.27mmol)和氨基乙醇(64.3mg,0.54mmol)的甲醇(10mL)和二氯甲烷(10mL)混合溶液中加入冰醋酸(32.4mg,0.54mmol),反应液在室温下搅拌1小时。然后,加入氰基硼氢化钠(84.8mg,1.35mmol)搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用水(20mL)和饱和食盐水(20mL)各洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶薄层层析制备板纯化(二氯甲烷:甲醇=10:1)得化合物1(24mg,产率:18.9%)。LC-MS(ESI):m/z=669.0[M+H]+.
1H NMR(400MHz,CD3OD):δ8.15(s,2H),7.84-7.83(d,J=8.0Hz,2H),7.67-7.59(m,6H),7.41-7.33(m,4H),7.14-7.13(d,J=6.5Hz,2H),4.41(s,4H),3.88-3.86(m,4H),3.25-3.23(m,4H),2.20(s,6H).
实施例2
(2S)-3-羟基-2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-羟乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-甲基苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-2-甲基丙酸2
化合物2-e的合成
在室温下,往化合物1-b(559mg,1.275mmol)的四氢呋喃(10mL)和甲醇(10mL)混合溶液中加入硼氢化钠(96.5mg,2.551mmol),反应液搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用水(20mL)和饱和食盐水(20mL)各洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1)得化合物2-e(517mg,产率:92.5%)。
化合物2-d的合成
在室温下,往化合物2-e(517mg,1.174mmol)的二氯甲烷(10mL)溶液中加入氯化亚砜(698.4mg,5.87mmol)和2滴N,N-二甲基甲酰胺,反应液搅拌16小时。反应液减压浓缩,所得油状物用乙酸乙酯(20mL)溶解,经饱和碳酸氢钠水溶液(20mL)洗涤两次,饱和食盐水(20mL)洗涤一次,所得有机相经无水硫酸钠干燥,减压浓缩得化合物2-d(500mg,产率:92.9%),直接用于下一步反应。
1H NMR(400MHz,CDCl3):δ7.78(s,1H),7.73-7.71(d,J=8.0Hz,1H),7.62-7.60(d,J=8.0Hz,1H),7.47-7.45(d,J=8.0Hz,1H),7.40-7.32(m,2H),7.29-7.25(m,2H),4.69(s,2H),2.47(m,3H).
化合物2-c的合成
往化合物2-d(500mg,1.09mmol)和(S)-2-甲基丝氨酸甲酯对甲苯磺酸盐(332.8mg,1.09mmol)的乙腈(20mL)溶液中加入碘化钠(32.7mg,0.218mmol)和碳酸钾(753.2mg,5.45mmol),反应液加热至80℃,在氮气保护下搅拌16小时。反应液冷却至室温,加乙酸乙酯(20mL)稀释后,用水(20mL)用饱和硫代硫酸钠水溶液(20mL)洗涤两次,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,所得的剩余物经硅胶薄层层析制备板纯化(石油醚:乙酸乙酯=5:1)得化合物2-c(471mg,产率:77.7%)。
1H NMR(400MHz,CDCl3):δ7.74(s,1H),7.68-7.67(d,J=8.5Hz,1H),7.61-7.60(d,J=7.5Hz,1H),7.44-7.42(d,J=8.0Hz,1H),7.40-7.37(m,1H),7.35-7.31(t,1H),7.28-7.24(m,2H),3.84-3.83(d,J=2.0Hz,2H),3.81(s,3H),3.79-3.77(d,J=11.0Hz,1H),3.68-3.66(d,J=11.0Hz,1H),2.47(s,3H),1.42(s,3H).
化合物2-b的合成
往化合物2-c(471mg,0.848mmol)和化合物1-d(423.3mg,1.017mmol)的1,4-二氧六环(20mL)和水(1mL)混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(73.4mg,0.0848mmol)和碳酸钠(224.7mg,2.12mmol),反应液在氮气保护下加热至80℃,并搅拌16小时。反应液冷却至室温,加乙酸乙酯溶液(20mL)稀释后,用水(20mL)洗涤三次,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶薄层层析制备板纯化(石油醚:乙酸乙酯=1:1)得化合物2-b(459mg,产率:77.9%)。LC-MS(ESI):m/z=696.0[M+H]+.
化合物2-a的合成
在室温下,往化合物2-b(459mg,0.66mmol)和氨基乙醇(80.6mg,1.32mmol)的甲醇(10mL)和二氯甲烷(10mL)混合溶液中加入冰醋酸(79.3mg,1.32mmol),反应液搅拌1小时后加入氰基硼氢化钠(207.4mg,3.30mmol),搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用水(20mL)和饱和食盐水(20mL)各洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶薄层层析制备板纯化(二氯甲烷:甲醇=10:1)得化合物2-a(32mg,产率:6.6%)。LC-MS(ESI):m/z=741.0[M+H]+.
化合物2的合成
在室温下,往化合物2-a(100mg,0.27mmol)的甲醇(10mL)和水(10mL)混合溶液中加入氢氧化钠(32.4mg,0.54mmol),并继续搅拌16小时。反应液减压浓缩,剩余物用水(20mL)稀释,用稀盐酸(1.0M)调节pH至4~5,有白色沉淀析出。过滤,滤饼用水(5mL)洗后,经真空干燥后得到化合物2(30mg,产率:98%)。LC-MS(ESI):m/z=727.0[M+H]+.
1H NMR(400MHz,CD3OD):δ8.20-8.16(d,J=19.0Hz,2H),7.85-7.81(m,2H),7.69-7.59(m,6H),7.42-7.33(m,4H),7.15-7.12(m,2H),4.41(s,2H),4.39-4.30(m,2H),4.05-4.02(d,J=12.5Hz,1H),3.88-3.85(m,3H),3.25-3.23(m,2H),2.21-2.20(d,J=4.0Hz,6H),1.59(s,3H).
实施例3
(2S)-2-[({3-[(E)-2-(3-{3-[(E)-2-[5-({[(1S)-1-羧基-2-羟基-1-甲基乙基]氨基}甲基)-2-(三氟甲基)苯基]乙烯基]-2-甲基苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-3-羟基-2-甲基丙酸3
化合物3-c的合成
室温下,往化合物1-a(381mg,0.659mmol)的四氢呋喃(10mL)和甲醇(10mL)的混合溶液中加入硼氢化钠(124.6mg,3.293mmol),反应液在室温下搅拌16小时。反应液减压浓缩,剩余物用乙酸乙酯(20mL)溶解后,用水(20mL)和饱和食盐水(20mL)各洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1~5:1)得化合物3-c(367mg,产率:96.3%)。
化合物3-b的合成
在室温下,往化合物3-b(367mg,0.63mmol)的二氯甲烷(20mL)溶液中加入氯化亚砜(374.7mg,3.15mmol)和2滴N,N-二甲基甲酰胺,反应液搅拌16小时。反应液减压浓缩,所得油状物用乙酸乙酯(20mL)溶解,经饱和碳酸氢钠水溶液(20mL)洗涤两次,饱和食盐水(20mL)洗涤一次,所得有机相经无水硫酸钠干燥,减压浓缩得化合物3-b(333mg,产率:85.4%),直接用于下一步反应。
化合物3-a的合成
往化合物3-b(333mg,0.538mmol)和(S)-2-甲基丝氨酸甲酯对甲苯磺酸盐(328.3mg,1.075mmol)的乙腈(20mL)溶液中加入碳酸钾(743.6mg,5.38mmol)和碘化钠(40.3mg,0.269mmol),反应液加热至80℃,在氮气保护下搅拌16小时。反应液冷却至室温,加乙酸乙酯(20mL)稀释后,用水(20mL)用饱和硫代硫酸钠水溶液(20mL×2)洗涤,饱和食盐水(20mL)洗涤一次。有机相经无水硫酸钠干燥,减压浓缩,所得的剩余物经硅胶薄层层析制备板纯化(二氯甲烷:甲醇=15:1)得化合物3-a(360mg,产率:82.6%)。LC-MS(ESI):m/z=813.0[M+H]+.
化合物3的合成
在室温下,往化合物3-a(360mg,0.443mmol)的甲醇(20mL)和水(2mL)混合溶液中加入氢氧化钠(88.6mg,2.215mmol),并继续搅拌16小时。反应液减压浓缩,剩余物用水(20mL)稀释,用稀盐酸(1.0M)调节pH至4~5,有白色沉淀析出。过滤,滤饼用水(5mL)洗后,经真空干燥后得到化合物3(264mg,产率:74.8%)。LC-MS(ESI):m/z=785.0[M+H]+.
1H NMR(400MHz,CD3OD):δ8.19(s,2H),7.82-7.81(d,J=8.5Hz,2H),7.69-7.61(m,6H),7.41-7.38(m,2H),7.35-7.32(m,2H),7.14-7.13(d,J=7.5Hz,2H),4.39-4.31(m,4H),4.06-4.03(d,J=12.5Hz,2H),3.88-3.86(d,J=12.5Hz,2H),2.20(s,6H),1.60(s,6H).
实施例4
2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-甲氧基乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-氯苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-1-乙醇4
化合物4-f的合成
将3-溴-4-三氟甲基苯甲醛(4.0g,15.8mmol)和乙烯硼酸酯(2.92g,18.9mmol)溶于甲苯(100mL)中,向溶液中加入二(三叔丁基磷)化钯(807mg,1.58mmol)和三乙胺(4.78g,47.4mmol)。反应液在氮气保护下于80℃搅拌5小时,薄层层析监测原料反应完全。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50-10:1),得到棕色粘稠物4-f(300mg,产率:58%).
化合物4-e的合成
将化合物1-溴-2-氯-3-碘苯(2.0g,8.2mmol)和化合物4-f(3.0g,9mmol)溶于二氧六环和水的混合溶液(50mL/5mL)中,向溶液中加入四(三苯基膦)钯(947mg,0.82mmol),碳酸钠(2.60g,24.6mmol)。反应液在氮气保护下于70℃搅拌12小时,薄层层析监测原料反应完全。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=100-10:1),得到白色固体4-e(1.15g,产率:36%)。
化合物4-d的合成
将化合物4-e(760mg,2.0mmol)和2-甲氧基乙胺(450mg,6.0mmol)溶于二氯甲烷(30ml)和MeOH(10ml)的混合溶液中,在常温下向反应液加入冰醋酸(360mg,6.0mmo),反应液搅拌2小时后,向反应液中加入氰基硼氢化钠(152mg,4.0mmol),继续搅拌18个小时,薄层层析监测原料反应完全。减压浓缩,剩余物溶于二氯甲烷(80mL)中,用水(50mL)和饱和食盐水(30mL)洗涤,无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=20-5:1),得到褐色固体4-d(700mg,产率:78%)。
1H NMR(400MHz,CD3OD)δ:7.79(s,1H),7.66-7.60(m,3H),7.49(s,1H),7.42-7.40(m,2H),7.19(t,J=6.0Hz,1H),3.94(s,2H),3.56(t,J=4.0Hz,2H),3.39(s,3H),2.86(t,J=4.0Hz,2H).
化合物4-c的合成
将化合物4-d(350mg,0.78mmol)和二碳酸二叔丁酯(340mg,1.56mmol)溶于二氯甲烷(30ml),依次加入三乙胺(315.1mg,3.12mmol)和4-二甲氨基吡啶(9.5mg,0.078mmol),反应液在常温下搅拌过夜。向反应体系加入二氯甲烷(60mL)稀释,依次用水(50ml)和饱和食盐水(40ml)洗涤,无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=20-10:1),得到黄色油状物4-c(400mg,产率:93%)。
1H NMR(400MHz,CD3OD):δ7.69-7.60(m,4H),7.50-7.46(m,1H),7.48-7.42(m,1H),7.32-7.27(m,1H),7.19(t,J=6.4Hz,1H),4.62(d,J=9.2Hz,2H),3.57-3.40(m,4H),3.34(s,3H),1.54-1.39(m,9H).
化合物4-b的合成
将化合物4-c(165mg,0.3mmol)和1-d(137mg,0.33mmol)溶于二氧六环和水的混合溶液(40mL/4mL)中,向溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(44mg,0.06mmol),碳酸钠(127mg,1.2mmol)。反应液在氮气保护下于85℃下搅拌12小时。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=20-5:1),得到黄色固体4-b(150mg,产率:66%)。
1H NMR(400MHz,CD3OD):δ10.17(s,1H),8.31(s,1H),7.90(s,1H),7.89(s,1H),7.76-7.65(m,4H),7.60-7.34(m,6H),7.25-7.18(m,3H),4.62(d,J=8.4Hz,2H),3.56-3.39(m,4H),3.33(s,3H),2.24(s,3H),1.45-1.39(m,9H).
化合物4-a的合成
将化合物4-b(130mg,0.17mmol)和乙醇胺(52mg,0.85mmol)溶于二氯甲烷(10mL)和甲醇(3mL)的混合溶液中,下向反应液加入1滴冰醋酸。反应混合物于室温搅拌2小时后,向反应液中加入氰基硼氢化钠(21mg,0.33mmol),加毕,室温继续反应12小时。减压浓缩,剩余物经硅胶柱层析纯化(二氯甲烷:甲醇=20-10:1),得到黄色油状物4-a(130mg,产率:94%)。
化合物4的合成
将化合物4-a(130mg,0.16mmol)溶解于二氯甲烷(20mL)中,滴加三氟乙酸(1mL)保温至30℃下搅拌5小时。减压浓缩,所得剩余物经高效液相制备纯化得到白色固体4(65mg,产率:58%)。LC-MS(ESI):m/z=703.2[M-1]+.
1H NMR(400MHz,CD3OD):δ8.14(d,J=4.8Hz,1H),7.87-7.74(m,4H),7.66-7.47(m,6H),7.42-7.34(m,2H),7.30(d,J=10.6Hz,1H),7.16(d,J=6.4Hz,1H),4.40(s,2H),4.39(s,2H),3.87-3.85(m,2H),3.71-3.69(m,2H),3.43(s,3H),3.33-3.30(m,2H),3.24-3.22(m,2H),2.23(s,3H).
实施例5
(2S)-3-羟基-2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-甲氧基乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-氯苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-2-甲基丙酸5
化合物5-a的合成
将化合物(S)-2-氨基-3-羟基-2-甲基丙酸(72mg,0.60mmol)加到甲醇(20ml)中,在室温搅拌下,慢慢滴加氢氧化钠(24mg,0.6mmol)水溶液(5mL),反应体系逐渐澄清。继续搅拌1小时后,向反应体系里滴加化合物4-b(150mg,0.2mmol)的THF(5ml)溶液。滴加完毕后,继续搅拌过夜。向体系加入氰基硼氢化钠(25.2mg,0.4mmol),搅拌2小时。减压浓缩,剩余物用水(3mL)洗涤,得到粗产物5-a(160mg)。直接用于下一步反应。LC-MS(ESI):m/z=861[M+H]+.
化合物5的合成
将化合物5-a(160mg)溶解于二氯甲烷(15mL)中,滴加三氟乙酸(1mL),于30℃下搅拌5小时。TCL监测原料反应完全。减压浓缩,剩余物经高效液相制备纯化得白色固体5(31mg,产率:20%)。LC-MS(ESI):m/z=761.2[M+H]+.
1H NMR(400MHz,CD3OD):δ8.17(s,1H),7.97(s,1H),7.80-7.61(m,7H),7.53-7.33(m,5H),7.27(d,J=6.0Hz,1H),7.15(d,J=5.6Hz,1H),4.30-4.22(q,2H),3.98-3.96(m,3H),3.82(d,J=9.6Hz,1H),3.56(t,J=4.4Hz,2H),3.37(s,3H),2.85(t,J=4.4Hz,2H),2.23(s,3H),1.53(s,3H).
实施例6
(2S)-3-羟基-2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-羟基乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-氯苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-2-甲基丙酸6
化合物6-d的合成
将化合物4-e(450mg,1.15mmol)和2-氨基乙醇(211mg,3.47mmol)溶于二氯甲烷(30mL)和甲醇(10mL)的混合溶液中,加入冰醋酸(0.1mL),反应混合物于室温搅拌2小时后,加入氰基硼氢化钠(114mg,2.30mmol),加毕,继续搅拌反应18个小时。减压浓缩,剩余物溶于二氯甲烷(50mL),依次用水(50mL)和饱和食盐水(30mL)洗涤,无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(甲醇:乙酸乙酯=1-20:100),得到白色固体6-d(430mg,产率:86%)。
1H NMR(400MHz,CD3OD):δ7.77(s,1H),7.67-7.60(m,3H),7.52-7.38(m,3H),7.19(t,J=6.4Hz,1H),3.95(s,2H),3.74(t,J=4.0Hz,2H),2.88(t,J=4.0Hz,2H).
化合物6-c的合成
将化合物6-d(430mg,1.0mmol)和二碳酸二叔丁酯(436mg,2.0mmol)溶于二氯甲烷(40mL),依次加入三乙胺(404mg,4.0mmol)和4-N,N-二甲基吡啶(122mg,1.0mmol),反应液于室温搅拌过夜。向反应体系加入二氯甲烷(60mL)稀释,依次用水(50mL)和饱和食盐水(30mL)洗涤,无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50-15:1),得到黄色油状物6-c(100mg,产率:18%)。LC-MS(ESI):m/z=536.0[M+H]+.
化合物6-b的合成
将化合物6-c(100mg,0.2mmol)和1-d(100mg,0.24mmol)溶于二氧六环和水的混合溶液(20mL/2mL)中,向溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(29.2mg,0.04mmol),碳酸钠(63.6mg,0.6mmol)。反应液在85℃下搅拌10小时。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10-2:1),得到透明油状产物6-b(100mg,产率:66%)。LC-MS(ESI):m/z=744.1[M+H]+.
化合物6-a的合成
将化合物(S)-2-氨基-3-羟基-2-甲基丙酸(47.6mg,0.40mmol)加到甲醇(10ml)中,在室温搅拌下,慢慢滴加氢氧化钠(16mg,0.4mmol)水溶液(3ml),反应体系逐渐澄清,继续搅拌1小时后,慢慢滴加6-b(100mg,0.13mmol)的THF(4mL)溶液。滴加完毕后,继续搅拌过夜。向体系中加入氰基硼氢化钠(12.6mg,0.2mmol),搅拌2小时。减压浓缩,所得物用水(3mL)洗涤,得到粗产物6-a(160mg)。直接用于下一步反应。LC-MS(ESI):m/z=861.0[M+H]+.
化合物6的合成
将化合物6-a(160mg)溶解于二氯甲烷(10mL)中,滴加三氟乙酸(1mL),于30℃下搅拌5小时。薄层层析监测原料反应完全。减压浓缩,剩余物经高效液相制备纯化得到白色固体产物6(9mg,产率:10%)。LC-MS(ESI):m/z=374.2[M/2+H]+.
1H NMR(400MHz,CD3OD):δ8.17(s,1H),8.13(s,1H),7.87-7.74(m,4H),7.67-7.63(m,4H),7.55-7.34(m,4H),7.30(d,J=6.4Hz,1H),7.1(d,J=5.6Hz,1H),4.42-4.38(m,4H),4.10(d,J=9.2Hz,1H),3.90(d,J=8.8Hz,1H),3.87-3.85(m,2H),3.24-3.22(m,2H),2.23(s,3H),1.64(s,3H).
实施例7
2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-羟基乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-氯苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-1-乙醇7
化合物7-a的合成
将化合物6-b(168mg,0.2mmol)和2-氨基乙醇(35mg,0.6mmol)溶于二氯甲烷(20ml)和MeOH(5ml)的混合溶液中,向反应液加入冰醋酸(0.1mL),于室温搅拌2小时后,加入氰基硼氢化钠(25mg,0.4mmol),加毕,继续搅拌反应18个小时。减压浓缩,残余物溶于二氯甲烷(50mL),依次用水(50mL)和饱和食盐水(30mL)洗涤,无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(甲醇:乙酸乙酯=1-20:100),得到无色粘稠物7-a(120mg,产率:67%)。LC-MS(ESI):m/z=789.2[M+H]+.
化合物6的合成
将化合物7-a(120mg,0.13mmol)溶解于二氯甲烷(10mL)中,滴加三氟乙酸(1mL),于30℃下搅拌5小时。减压浓缩,所得物经高效液相制备纯化得到白色固体产物7(40mg,产率:43%)。LC-MS(ESI):m/z=689.3[M+H]+.
1H NMR(400MHz,CD3OD):δ7.98(s,1H),7.96(s,1H),7.76(d,J=4.2Hz,1H),7.72-7.31(m,8H),7.53-7.33(m,5H),7.27(d,J=6.4Hz,1H),7.13(d,J 6.0Hz,1H),3.93(s,4H),3.72-3.70(m,4H),2.79-2.70(m,4H),2.22(s,3H).
实施例8
(2S)-3-羟基-2-[({3-[(E)-2-[3-(3-(E)-{2-[2-氟-5-(2-甲氧基乙氧基)苯基]乙烯基}-2-甲基苯基)-2-甲基苯基]乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-2-甲基丙酸8
化合物8-g的合成
在常温条件下,往3-溴-4-氟苯酚(1.0g,5.24mmol)和1-溴-2-甲氧基乙烷(800mg,5.76mmol)的DMF(20mL)溶液中加入碘化钠(157mg,1.05mmol)和碳酸钾(3.62g,26.2mmol),反应混合物于80℃条件下搅拌过夜。反应结束后,反应液用乙酸乙酯稀释,水洗(100mL),饱和食盐水洗(100mL)。所得有机相经无水硫酸钠干燥,减压浓缩,剩余物经硅胶柱纯化(石油醚:乙酸乙酯=50:1~10:1),得到8-g(1.263g,产率:96.9%)。
1H NMR(500MHz,CDCl3):δ7.14-7.12(1H,dd,J=.0Hz,J=.5Hz),7.07-7.03(1H,dd,J=.5Hz,J=9.5Hz),6.88-6.85(1H,m),4.10-4.08(2H,m),3.76-3.75(2H,m),3.47(3H,s).
化合物8-f的合成
往8-g(1.263g,5.07mmol)和1-f(1.694g,6.08mmol)的1,4-二氧六环(20mL)和水(1mL)混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(438mg,0.507mmol)和碳酸钠(1.344g,12.67mmol),反应液加热至80℃,在氮气保护下搅拌反应过夜。减压浓缩,剩余物经硅胶柱纯化(PE:EA=50:1~10:1),得到8-f(1.20g,产率:73.9%)。
化合物8-e的合成
往8-g(1.20g,3.74mmol)和联硼酸频哪醇酯(1.14g,4.49mmol)的甲苯(20mL)溶液中加入三(二亚苄基丙酮)二钯(171mg,0.187mmol),2-二环己基磷-2',4',6'-三异丙基联苯(356.6mg,0.748mmol)和醋酸钾(1.101g,11.22mmol),反应液加热至90℃,在氮气保护下搅拌反应过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50:1~10:1),得到8-e(336mg,产率:21.7%)。
1H NMR(500MHz,CDCl3):δ7.74-7.72(d,J=.5Hz,1H),7.68-7.67(d,J=.5Hz,1H),7.49-7.45(d,J=6.0Hz,1H),7.25-7.20(m,2H),7.08-7.05(d,J=16.5Hz,1H),7.02-6.99(t,J=9.0Hz,1H),6.81-6.79(m,1H),4.17-4.14(m,2H),3.80-3.78(m,2H),3.50(s,3H),2.64(3H,s),1.39(s,12H).
化合物8-d的合成
往8-e(336mg,0.815mmol)和1-b(297mg,0.679mmol)的乙二醇二甲醚(10mL)溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(58mg,0.068mmol)和氟化铯(258mg,1.70mmol),反应液在氮气保护下于80℃搅拌过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=20:1~5:1),得到8-d(100mg,产率:25.6%)。
化合物8-c的合成
往8-d(100mg,0.174mmol)的四氢呋喃(5mL)和甲醇(5mL)混合溶液中加入硼氢化钠(13mg,0.348mmol),反应液在在室温下搅拌过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1~3:1),得到8-c(80mg,产率:80%)。
1H NMR(500MHz,CDCl3):δ7.71(s,1H),7.59-7.52(m,3H),7.39-7.36(d,J=16.0Hz,1H),7.32(s,2H),7.28-7.27(d,J=8.0Hz,1H),7.22-7.17(m,2H),7.11-7.00(m,4H),6.93-6.89(t,J=9.0H,1Hz),6.72-6.70(m,1H),4.72(s,2H),4.06-4.03(m,2H),3.69-3.67(m,2H),3.38(s,3H),2.07(s,3H),2.06(s,3H).
化合物8-b的合成
往8-c(80mg,0.139mmol)的二氯甲烷(50mL)溶液中加入氯化亚砜(82mg,0.694mmol),反应液搅拌过夜。反应结束后,将有机溶剂旋干,剩余物用油泵抽干后,得到8-b(82mg,产率:99%),直接用于下一步反应。
化合物8-a的合成
往8-b(82mg,0.138mmol)和(S)-2-甲基丝氨酸甲酯对甲苯磺酸盐(84mg,0.28mmol)的乙腈(10mL)溶液中加入碘化钠(10mg,0.068mmol)和K2CO3(191mg,1.38mmol),反应液在氮气保护下于80℃搅拌过夜。反应结束后,旋干溶剂,残留物用乙酸乙酯溶解(100mL),依次用饱和硫代硫酸钠水溶液(100mL×2),饱和食盐水(100mL×1)洗涤。所得有机相经无水硫酸钠干燥,旋干后得到粗品化合物,经制备板纯化(石油醚:乙酸乙酯=2:1)后得到目标化合物8-a(23mg,产率:24.2%)。LC-MS(ESI):m/z=692.0[M+H]+.
化合物8的合成
往8-a(23mg,0.033mmol)的甲醇(10mL)和水(1mL)混合溶液中加入氢氧化钠(6mg,0.15mmol),室温搅拌过夜。反应结束后,将溶剂旋干,剩余物加水稀释后,用稀盐酸(1M)调节溶液pH=4~5,沉淀析出白色固体。过滤,干燥,得到8(20mg)。LC-MS(ESI):m/z=678.0[M+H]+.
1H NMR(500MHz,CD3OD):δ8.22(1H,s),7.84-7.82(d,J=8.5Hz,1H),7.70-7.56(m,5H),7.41-7.25(m,4H),7.17-7.03(m,4H),6.89-6.87(m,1H),4.43(s,2H),4.16-4.10(m,4H),3.77-3.76(m,2H),3.45(s,3H),2.19(s,3H),2.15(s,3H),1.69(s,3H).
实施例9
2-({[(3-(E)-2-{3-[3-(3-{[(2-羟基乙基)氨基]甲基}苯基)-2-甲基苯基]-2-甲基苯基}乙烯基)-4-(三氟甲基)苯基]甲基}氨基)-1-乙醇9
化合物9-b的合成
往3-甲酰基苯硼酸(1.0g,6.67mmol)和2,6-二溴甲苯(2.5g,10.0mmol)的1,4-二氧六环(30mL)和水的(1.5mL)混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(577mg,0.667mmol)和碳酸钠(1.768g,16.675mmol),反应液在氮气保护下加热于80℃搅拌过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50:1~10:1)得到目标化合物9-b(1.106g,产率:60.1%)。
1H NMR(500MHz,CDCl3):δ10.0(s,1H),7.83-7.81(m,1H),7.73(m,1H),7.55-7.47(m,3H),7.11-7.09(dd,J=1.0Hz,J=7.5Hz,1H),7.06-7.03(t,J=8.0Hz,1H),2.23(s,3H).
化合物9-a的合成
往9-b(1.106g,4.02mmol)和1-d(2.00g,4.8mmol)的乙二醇二甲醚(20mL)溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(348mg,0.402mmol)和氟化铯(1.527g,10.05mmol),反应液,在氮气保护下于80℃搅拌过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=10:1~3:1)得到9-a(1.69g,产率:86.7%)。
1H NMR(500MHz,CDCl3):δ10.07(s,1H),10.01(s,1H),8.21(s,1H),7.83-7.79(m,4H),7.60-7.52(m,3H),7.46-7.43(d,J=15.5Hz,1H),7.35-7.31(m,1H),7.27-7.23(m,2H),7.19-7.17(m,1H),7.11-7.10(m,2H),2.14(s,3H),1.87(s,3H).
化合物9的合成
在常温条件下,往9-a(100mg,0.206mmol)和乙醇胺(25mg,0.41mmol)的甲醇(10mL)和二氯甲烷(10mL)混合溶液中加入冰醋酸(25mg,0.41mmol),反应混合物搅拌1小时,然后加入氰基硼氢化钠(63mg,1.0mmol),室温搅拌过夜。旋干溶剂,剩余物经高效液相制备纯化得到目标化合物9(54mg,产率:45%)。LC-MS(ESI):m/z=575.0[M+H]+.
1H NMR(500MHz,CD3OD):δ8.14(s,1H),7.85-7.83(d,J=8.0Hz,1H),7.66-7.47(m,7H),7.41-7.33(m,3H),7.28-7.26(dd,J=1.5Hz,J=7.5Hz,1H),7.17-7.14(m,2H),4.41(s,2H),4.34(s,2H),3.88-3.84(m,4H),3.24-3.22(m,2H),3.20-3.18(m,2H),2.22(s,3H),1.96(s,3H).
实施例10
2-({[(3-(E)-2-{3-[3-(5-{[(2-羟基乙基)氨基]甲基}-2-氟-苯基)-2-甲基苯基]-2-甲基苯基}乙烯基)-4-(三氟甲基)苯基]甲基}氨基)-1-乙醇10
化合物10-c的合成
往3-溴-4-氟苯甲醛(1.0g,4.93mmol)和联硼酸频哪醇酯(1.5g,5.91mmol)的甲苯(30mL)溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(426mg,0.493mmol)和醋酸钾(1.452g,14.79mmol),反应液,在氮气保护下于80℃搅拌过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50:1~10:1),得到10-c(1.1g,产率:90.2%)。
1H NMR(500MHz,CDCl3):δ10.00(s,1H),8.32-8.31(m,1H),8.04-8.01(m,1H),7.22-7.19(t,J=9.0Hz,1H),1.40(s,12H).
化合物10-b的合成
往10-c(1.11g,4.439mmol)和2,6-二溴甲苯(1.664g,6.658mmol)的1,4-二氧六环(30mL)和水的(1.5mL)混合溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(384mg,0.444mmol)和碳酸钠(1.177g,11.1mmol),反应液加热至80℃,在氮气保护下搅拌反应过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=50:1~10:1),得到目标化合物10-b(605mg,产率:46.5%)。
1H NMR(500MHz,CDCl3):δ9.94(s,1H),7.89-7.85(m,1H),7.74-7.73(m,1H),7.58-7.56(dd,J=2.0Hz,J=7.5Hz,1H),7.26-7.23(t,J=9.0Hz,1H),7.11-7.05(m,2H),2.18(s,3H).
化合物10-a的合成
往10-b(0.605g,2.064mmol)和1-d(1.031g,2.477mmol)的乙二醇二甲醚(20mL)溶液中加入[1,1’-双(二苯基磷)二茂铁]二氯化钯(178.2mg,0.206mmol)和氟化铯(784mg,5.16mmol),反应液加热至80℃,在氮气保护下搅拌反应过夜。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=20:1~3:1),得到目标化合物10-a(0.587g,产率:56.4%)。
1H NMR(500MHz,CDCl3):δ10.08(s,1H),9.96(s,1H),8.21(s,1H),7.88-7.80(m,4H),7.56-7.55(d,J=7.5Hz,1H),7.46-7.43(d,J=16.5Hz,1H),7.35-7.31(m,1H),7.29-7.23(m,3H),7.16-7.11(m,3H),2.13(s,3H),1.82(s,3H).
化合物10的合成
往10-a(100mg,0.199mmol)和乙醇胺(24.3mg,0.398mmol)的甲醇(10mL)和二氯甲烷(10mL)混合溶液中加入冰醋酸(23.9mg,0.398mmol),反应混合物搅拌1小时,然后加入氰基硼氢化钠(62.5mg,0.995mmol),搅拌过夜。反应结束后,将溶剂旋干,剩余物用高效液相制备纯化得到目标化合物10(112mg,产率:95%)。LC-MS(ESI):m/z=593.0[M+H]+.
1H NMR(500MHz,CD3OD):δ8.15(s,1H),7.84-7.83(d,J=8.0Hz,1H),7.67-7.55(m,5H),7.41-7.27(m,5H),7.22-7.15(m,2H),4.41(s,2H),4.32(s,2H),3.88-3.84(m,4H),3.24-3.19(m,4H),2.22(s,3H),1.89(s,3H).
实施例11
(2S)-2-[({3-[(E)-2-(3-{3-[5-({[(1S)-1-羧基-2-羟基-1-甲基乙基]氨基}甲基)-2-氟苯基]-2-甲基苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-3-羟基-2-甲基丙酸11
化合物11的合成
将(S)-2-甲基丝氨酸(189.6mg,1.592mmol)悬浮于甲醇(5mL)中,慢慢滴加氢氧化钠(63.7mg,1.592mmol)溶于5mL水的溶液。反应液搅拌至澄清,然后加入10-a(100mg,0.199mmol)的四氢呋喃(5mL)溶液,反应搅拌过夜后,加入硼氢化钠(3mg,1.0mmol),继续搅拌半小时。用LC/MS监测反应进程,反应结束后,将溶剂旋干,剩余物用高效液相制备纯化得到化合物11(48mg,产率:34.1%)。LC-MS(ESI):m/z=709.0[M+H]+.
1H NMR(500MHz,CD3OD):δ8.18(s,1H),7.85-7.83(d,J=8.5Hz,1H),7.67-7.57(m,5H),7.42-7.29(m,5H),7.22-7.16(m,2H),4.44-4.38(dd,J=12.5Hz,J=4.5Hz,2H),4.37-4.31(dd,J=13.0Hz,J=4.5Hz,2H),4.15-4.10(t,J=12.0Hz,2H),3.94-3.90(m,2H),2.22(s,3H),1.91(s,3H),1.68(s,3H),1.66(s,3H).
实施例12
2-[({3-[(E)-2-(3-{3-[(E)-2-(5-{[(2-羟乙基)氨基]甲基}-2-(三氟甲基)苯基)乙烯基]-2-(氟甲基)苯基}-2-甲基苯基)乙烯基]-4-(三氟甲基)苯基}甲基)氨基]-1-乙醇12
/>
化合物12-b的合成
将2,6-二溴苯甲醇(2.40g,9.06mmol)悬浮于干燥二氯甲烷(60mL)中,于-78℃慢慢滴加二乙胺基三氟化硫(1.90mg,11.8mmol),加毕,于-78℃下继续搅拌1小时。TLC监测反应完全。将反应液慢慢加入到饱和碳酸氢钠水溶液中(150mL),分出有机相,水相用二氯甲烷萃取(30mL×2)。合并有机相,饱和食盐水洗(30mL),无水硫酸钠干燥。减压浓缩,剩余物经硅胶柱层析纯化(洗脱剂:石油醚),得到白色固体产物12-b(1.86g,产率:78%)。
化合物12-a的合成
向100毫升三口烧瓶中加入12-b(268mg,1.0mmol),4-f(391mg,1.2mmol),1-d(541mg,1.3mmol),氟化铯(600mg,4.0mmol),磷酸钾(848mg,4.0mmol),[1,1’-双(二苯基磷)二茂铁]二氯化钯(120mg,0.16mmol)以及甲苯(25mL)。反应混合混合物在氮气保护于80℃下搅拌反应6小时。减压浓缩,剩余物经硅胶柱层析纯化(石油醚:乙酸乙酯=100:1~8:1),得到浅黄色固体12-a(306mg,产率:44%)。
化合物12的合成
向12-a(150mg,0.25mmol)的二氯甲烷(10mL)溶液中,加入乙醇胺(61mg,1.0mmol),甲醇(10mL),冰醋酸(20mg,0.34mmol)。反应混合物搅拌1小时后,加入氰基硼氢化钠(63mg,1.0mmol)。加毕,继续搅拌16小时。减压旋除溶剂,剩余物经硅胶柱层析纯化(二氯甲烷:7N氨的甲醇溶液=15:1),得到类白色固体12(54mg,产率:31%)。LC-MS(ESI):m/z=687[M+H]+.
1H NMR(400MHz,CD3OD):δ7.98(s,1H),7.97(s,1H),7.75(d,J=7.6Hz,1H),7.69-7.72(m,3H),7.61-7.65(m,2H),7.52-7.57(m,2H),7.45~7.48(m,2H),7.37~7.42(m,1H),7.31~7.35(m,1H),7.22(d,J=7.6Hz,1H),7.15(d,J=7.2Hz,1H),5.36~5.45(m,1H),5.24~5.33(m,1H),3.93(s,2H),3.92(s,2H),3.71(d,J=5.2Hz,4H),2.76-2.79(m,4H),2.19(s,3H).
效果实施例
采用均相时间分辨荧光(Homogenouse Time-Resolved Fluorescence,HTRF)结合试验来检测本公开的化合物对PD-1/PD-L1的结合能力。
购买来的试剂盒(CisBio,#64CUS000C-1)中包含有PD-1、PD-L1、anti-tag1-Eu、Anti-tag2-XL665、Dilute Buffer和Detection Buffer等实验所需的试剂。
实验步骤
1.将化合物用100%DMSO配置成浓度梯度为3倍的10个浓度。
2.将化合物的DMSO溶液加入到稀释缓冲溶液(Dilute Buffer)中,混合均匀后转移到96孔板中。
3.将PD-L1用稀释缓冲溶液(Dilute Buffer)稀释,然后加入到上述96孔板中。
4.将PD-1用稀释缓冲溶液(Dilute Buffer)稀释,然后加入到上述96孔板中,并在室温下培养30分钟。
5.将一份anti-tag1-Eu和一份Anti-tag2-XL665加入到检测缓冲溶液(DetectionBuffer)中,混合均匀后转移到上述96孔板中。
6.此96孔板中的混合液在室温下培养1到24小时。
7.用Envision读取HTRF数值。
实验结果
本公开化合物的生物学活性通过以上的试验进行测定,测得的结果如下(表1):
表1本公开部分化合物对PD-1/PD-L1结合的IC50值
化合物 | IC50(μM) | 化合物 | IC50(μM) |
1 | 0.0061 | 2 | 0.0044 |
3 | 0.0032 | 4 | 0.0043 |
5 | 0.0023 | 6 | 0.0028 |
7 | 0.0026 | 8 | 0.510 |
9 | 0.0075 | 10 | 0.014 |
11 | 0.0087 | 12 | 0.0047 |
Claims (28)
1.一种通式I所示的联苯类化合物或其药学上可接受的盐:
其中,
环A和环B独立地为C6-C20芳环;
L1为乙炔基、-C(R5)=C(R6)-或-CR7R8-CR9R10-;L2为乙炔基、-C(R5)=C(R6)-、-CR7R8-CR9R10-或不存在;
R5、R6、R7、R8、R9和R10分别独立地为氢、氘、卤素、氰基或未取代的C1-C4烷基;
R1和R2独立地为氘、卤素、氰基或取代或未取代的C1-C4烷基;
每个R3和每个R4独立地为卤素、取代或未取代的C1-C4烷基或取代或未取代的C1-C4烷氧基;
R1和R2中所述的取代的C1-C4烷基中的取代基选自卤素、氰基、C1-C4烷基、羟基和C1-C4烷氧基中的一个或多个;
每个R3和每个R4中所述的取代的C1-C4烷基或所述的取代的C1-C4烷氧基中的取代基选自卤素、C1-C4烷基、羟基、C1-C4烷氧基和C1-C4羧基中的一个或多个;/>中,R17和R18独立地为氢、取代或未取代的C1-C4烷基、取代或未取代的C3-C6环烷基或取代或未取代的C1-C4烷氧基;或者R17、R18和与它们相连接的氮原子一起形成一个取代或未取代的5-7元碳杂环;所述碳杂环中,杂原子为N,或N和O,杂原子数为1-4个;每个R17和每个R18相同或不同;
R17和R18中所述的取代的C1-C4烷基、所述的取代的C3-C6环烷基、所述取代的C1-C4烷氧基和所述的取代的5-7元碳杂环中的取代基选自卤素、氰基、C1-C4烷基、取代的C1-C4烷基、羟基、C1-C.4烷氧基、C1-C4羧基、C1-C4酯基和C1-C4酰胺基中的一个或多个;取代基中,所述的取代的C1-C4烷基中的取代基选自卤素、羟基和/>中的一个或多个;/>中,Ra1和Rb1独立地为氢或/>Ra11为C1-C4的烷基;
当取代基为多个时,所述的取代基相同或不同;
m为1、2或3;
n为1、2或3。
2.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,所述C6-C20芳环为C6-C14芳环;
和/或,所述的卤素为氟、氯、溴或碘;
和/或,所述的C1-C4烷基是指包括1-4个碳原子的支链和直链的饱和脂族烃基;
和/或,所述的C1-C4烷氧基表示通过氧桥连接的具有所述碳原子数目的环状或者非环状烷基;
和/或,所述的5-7元碳杂环为氮杂环丁烷基、哌嗪基、哌啶基、吡咯烷基、吗啉基、二氢咪唑基、二氢吲哚基、二氢异噁唑基、二氢噁二唑基、二氢噁唑基、二氢吡嗪基、二氢吡唑基、二氢吡啶基、二氢嘧啶基、二氢吡咯基、二氢喹啉基、二氢四唑基、二氢***基或二氢氮杂环丁烷基。
3.如权利要求2所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
所述C6-C14芳环为C6-C10芳环;
和/或,所述的C1-C4烷基为甲基、乙基、正丙基、异丙基、正丁基、叔丁基或异丁基;
和/或,所述的C1-C4烷氧基为甲氧基、乙氧基、正丙氧基、异丙氧基或叔丁氧基。
4.如权利要求3所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
所述C6-C10芳环为苯、萘、四氢萘、2,3-二氢化茚、联苯、菲、蒽或苊。
5.如权利要求1-4任一项所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
L1为-C(R5)=C(R6)-;
和/或,L2为-C(R5)=C(R6)-或不存在;
和/或,R5、R6、R7、R8、R9和R10分别独立地为氢或氘;
和/或,R1为卤素、氰基、取代或未取代的C1-C4烷基;
和/或,R2中,所述的C1-C4烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
6.如权利要求5所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
L1为-CH=CH-;
和/或,L2为-CH=CH-或不存在;
和/或,R1中,所述的C1-C4烷基为甲基;
和/或,R1中,所述的取代的C1-C4烷基中的取代基为卤素或羟基。
7.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R1和R2独立地为卤素、C1-C4烷基或被卤素取代的C1-C4烷基;
或者,R3和R4为卤素;
或者,R3和R4为取代或未取代的C1-C4烷基,所述的取代的C1-C4烷基中的取代基为卤素、羟基、C1-C4烷氧基和C1-C4羧基中的一个或多个,当取代基为多个时,所述的取代基相同或不同,
或者,R3和R4为取代或未取代的C1-C4烷氧基,所述的取代的C1-C4烷氧基中的取代基为卤素、羟基、和C1-C4烷氧基中的一个或多个,当取代基为多个时,所述的取代基相同或不同。
8.如权利要求7所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R3和R4中,所述的取代的C1-C4烷基中的取代基为卤素和中的一个或多个;
或者,R3和R4中,所述的取代的C1-C4烷氧基中的取代基为C1-C4烷氧基。
9.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R1和R2独立地为卤素、C1-C4烷基或被F、Cl、Br和I中的一个或多个取代的C1-C4烷基;
或者,R3和R4为被卤素取代的C1-C4烷基,所述的被卤素取代的C1-C4烷基为被F、Cl、Br和I中的一个或多个取代的C1-C4烷基;
或者,R3和R4为被取代的C1-C4烷基;
或者,当R3为取代或未取代的C1-C4烷基时,R3位于环A上与L1相连的原子的间位或对位;
或者,当R4为取代或未取代的C1-C4烷基时,R4位于环B上与L2相连的原子的间位或对位;
或者,当R3为取代或未取代的C1-C4烷基时,环A上还有0、1或2个取代基;
或者,当R4为取代或未取代的C1-C4烷基时,环B上还有0、1或2个取代基;
或者,R3和R4为取代或未取代的C1-C4烷氧基,所述的取代的C1-C4烷氧基中的取代基为卤素、羟基、和C1-C4烷氧基中的一个或多个;
或者,当R3为取代或未取代的C1-C4烷氧基时,R3位于环A上与L1相连的原子的邻位或间位;
或者,当R4为取代或未取代的C1-C4烷氧基时,R4位于环B上与L2相连的原子的邻位或间位。
10.如权利要求9所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R1和R2中,被F、Cl、Br和I中的一个或多个取代的C1-C4烷基为-CH2F、-CHF2或-CF3;
或者,R3和R4中,所述被F、Cl、Br和I中的一个或多个取代的C1-C4烷基为-CF3;
或者,R3和R4中,所述的被取代的C1-C4的烷基为/>其中,R17和R18一个为H,另一个为被C1-C4烷氧基、羟基和羧基中的一个或多个取代的C1-C4烷基。
11.如权利要求9所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R3和R4中,当R3和R4为被取代的C1-C4烷基时,所述的被/>取代的C1-C4烷基为
12.如权利要求9所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
当R3为取代或未取代的C1-C4烷基时,当环A上还有1个取代基时,该取代基位于取代或未取代的C1-C4烷基的对位、间位或邻位。
13.如权利要求9所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
当R4为取代或未取代的C1-C4烷基时,当环B上还有1个取代基时,该取代基位于取代或未取代的C1-C4烷基的对位、间位或邻位。
14.如权利要求9所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
R3和R4为取代或未取代的C1-C4烷氧基,所述的取代的C1-C4烷氧基中的取代基为C1-C4烷氧基,当取代基为多个时,所述的取代基相同或不同。
15.如权利要求14所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,R3和R4中,所述的取代的C1-C4烷氧基为
16.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
基团为/>其中,R1和R2的定义均如权利要求1-4任一项所述;
或者,独立地为/>其中M1和N1为被/>取代的C1-C4烷基,或者M1和N1其中一个为被/>取代的C1-C4烷基,另一个为取代的C1-C4烷氧基;其中R17、R18、R3和R4的定义均同权利要求1-15任一项所述,n1和m1独立地为0、1或2。
17.如权利要求16所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
基团为/>
或者,独立地为/>M1和N1为/>或者M1和N1其中一个为/>另一个为被C1-C4烷氧基取代的C1-C4烷氧基;R3和R4为卤素、C1-C4烷基、被卤素取代的C1-C4烷基、C1-C4烷氧基或取代的C1-C4烷氧基,所述的取代的C1-C4烷氧基中的取代基为C1-C4烷氧基;R17和R18的定义均同权利要求1-15任一项所述。
18.如权利要求17所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
为/> 其中N1、R17和R18同权利要求16或17所述;
或者,为/> 其中M1、R17和R18的定义如权利要求16或17所述。
19.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,
独立地为/>
和/或,独立地为/>
20.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,所述的通式I所示的联苯类化合物选自下列任一化合物:
21.如权利要求1所述的通式I所示的联苯类化合物或其药学上可接受的盐,其特征在于,所述的通式I所示的联苯类化合物为通式I-A或II所示的联苯类化合物:
其中,环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求1-20任一项所述,M1和N1的定义同权利要求16-20任一项所述,n1为0、1或2,m1为0、1或2。
22.一种如权利要求21所述的通式I-A或II所示的联苯类化合物的制备方法,其特征在于,
通式I-A所示的化合物中,当M1和N1中含有-NH-或-COOH时,其采用下列方法制备:所述方法包括下列步骤:将通式II-F所示的化合物进行如下所示脱保护反应,制得所述的通式I-A所示的联苯类化合物,
其中环A、环B、L1、L2、R1、R2、R3、R4、M1和N1的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2,RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1与N1相同;或者,RIIF和M1相同,RIIF1为N1对应的含有氨基或羧基保护基的基团;或者RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1为N1对应的含有氨基或羧基保护基的基团;
通式II所示的联苯类化合物的制备方法采用下列任一方法:
(1)方法一包括下列步骤:将通式II-A所示的化合物和化合物II-A1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-A1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2;在此方法中,环A和环B中的相同;
(2)方法二包括下列步骤:将通式II-B所示的化合物和化合物II-B1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
/>
其中化合物II-B1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2,M为卤素;在此方法中,环A和环B中的相同;
(3)方法三包括下列步骤:将通式II-C所示的化合物和化合物II-C1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-C1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2;RIIC和RIIC1其中一个为另一个为/>在此方法中,环A和环B中的/>相同或不同;
(4)方法四包括下列步骤:将通式II-D所示的化合物和化合物II-D1进行如下所示的反应,制得所述的通式II所示的联苯类化合物,
其中化合物II-D1结构如下:或其酸式盐,
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2,RIID和RIID1其中一个为另一个为卤素,在此方法中,环A和环B中的/>相同或不同;
(5)方法五包括下列步骤:将通式II-E所示的化合物进行如下所示脱保护反应,制得所述的通式II所示的联苯类化合物,通式II所示的化合物中R17或R18中含有羧基;
/>
其中环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求21所述,n1为0、1或2,m1为0、1或2,RIIE和RIIE1为每个R17’和每个R18’相同或不同,且至少有一个有羧基保护基,不含羧基保护基的R17’和R18’分别与通式II中对应的R17和R18相同;此方法中,环A和环B中的/>相同或不同。
23.一种通式II-A、II-B、II-C、II-D、II-E和II-F所示的化合物:
环A、环B、L1、L2、R1、R2、R3、R4、R17和R18的定义均同权利要求1-20任一项所述,M1和N1的定义同权利要求16-20任一项所述,n1为0、1或2,m1为0、1或2;M为卤素,RIIC和RIIC1其中一个为另一个为/>RIID和RIID1其中一个为/>另一个为卤素,RIIE和RIIE1为/>每个R17’和每个R18’相同或不同,且至少有一个有羧基保护基,不含羧基保护基的R17’和R18’分别与通式II中对应的R17和R18相同;RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1与N1相同;或者,RIIF和M1相同,RIIF1为N1对应的含有氨基或羧基保护基的基团;或者RIIF为M1对应的含有氨基或羧基保护基的基团,RIIF1为N1对应的含有氨基或羧基保护基的基团。
24.一种如下所示的化合物:
/>
25.一种如权利要求1-20任一项所述的通式I所示的联苯类化合物或其药学上可接受的盐在制备PD-1抑制剂和/或PD-L1抑制剂中的应用。
26.一种如权利要求1-20任一项所述的通式I所示的联苯类化合物或其药学上可接受的盐中的一种或多种在制备用于预防、缓解或治疗癌症、感染、自身免疫性疾病或其相关疾病的药物中的应用。
27.如权利要求26所述的应用,所述癌症为肺癌、食管癌、胃癌、大肠癌、肝癌、鼻咽癌、脑肿瘤、乳腺癌、***、血癌和骨癌中的一种或多种。
28.一种药物组合物,其包括治疗和/或预防有效量的如权利要求1-20任一项所述的通式I所示的联苯类化合物或其药学上可接受的盐,及药学上可接受载体和/或稀释剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108139515A TWI833829B (zh) | 2018-11-02 | 2019-10-31 | 聯苯類化合物,其中間體,製備方法,藥物組合物及應用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811301041 | 2018-11-02 | ||
CN2018113010419 | 2018-11-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111138301A CN111138301A (zh) | 2020-05-12 |
CN111138301B true CN111138301B (zh) | 2024-01-05 |
Family
ID=70462980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911023996.7A Active CN111138301B (zh) | 2018-11-02 | 2019-10-25 | 联苯类化合物、其中间体、制备方法、药物组合物及应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210387941A1 (zh) |
EP (1) | EP3875458A4 (zh) |
JP (1) | JP2022513592A (zh) |
KR (1) | KR20210089195A (zh) |
CN (1) | CN111138301B (zh) |
AU (1) | AU2019373702A1 (zh) |
SG (1) | SG11202105850YA (zh) |
WO (1) | WO2020088357A1 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
EP4212529A1 (en) | 2018-03-30 | 2023-07-19 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
WO2022028557A1 (zh) * | 2020-08-07 | 2022-02-10 | 上海再极医药科技有限公司 | 18f标记的联苯类化合物、其中间体、制备方法、药物组合物及应用 |
CN114057589A (zh) * | 2020-08-07 | 2022-02-18 | 上海再极医药科技有限公司 | 18f标记的联苯类化合物、其中间体、制备方法、药物组合物及应用 |
AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
CN112479988B (zh) * | 2020-12-09 | 2024-05-03 | 药康众拓(江苏)医药科技有限公司 | 取代联苯类化合物及其制备方法、用途和药物组合物 |
CN117715653A (zh) | 2021-07-07 | 2024-03-15 | 爱黛儿公司 | 与社会支配性缺失或减少相关的疾病的动物模型以及用于预防或治疗所述疾病的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119263A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
WO2018195321A1 (en) * | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
SG10201800508SA (en) | 2013-09-06 | 2018-02-27 | Aurigene Discovery Tech Ltd | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
JP6521977B2 (ja) | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 免疫調節剤としての1,2,4−オキサジアゾール誘導体 |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
NZ750414A (en) * | 2016-07-05 | 2023-02-24 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
US10590105B2 (en) | 2016-07-08 | 2020-03-17 | Bristol-Meyers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP7106572B2 (ja) | 2016-12-20 | 2022-07-26 | ブリストル-マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
MA47099A (fr) | 2016-12-22 | 2021-05-12 | Incyte Corp | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs |
KR102641030B1 (ko) | 2016-12-22 | 2024-02-29 | 인사이트 코포레이션 | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
ES2934230T3 (es) * | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
CN107281484A (zh) | 2017-05-31 | 2017-10-24 | 深圳大学 | 用于制备乙肝疫苗的组合物及其制备方法和应用 |
-
2019
- 2019-10-25 EP EP19878365.6A patent/EP3875458A4/en not_active Withdrawn
- 2019-10-25 US US17/288,946 patent/US20210387941A1/en active Pending
- 2019-10-25 AU AU2019373702A patent/AU2019373702A1/en not_active Abandoned
- 2019-10-25 WO PCT/CN2019/113209 patent/WO2020088357A1/zh unknown
- 2019-10-25 KR KR1020217016692A patent/KR20210089195A/ko active Search and Examination
- 2019-10-25 CN CN201911023996.7A patent/CN111138301B/zh active Active
- 2019-10-25 SG SG11202105850YA patent/SG11202105850YA/en unknown
- 2019-10-25 JP JP2021524391A patent/JP2022513592A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119263A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
WO2018195321A1 (en) * | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
TW202024019A (zh) | 2020-07-01 |
SG11202105850YA (en) | 2021-07-29 |
JP2022513592A (ja) | 2022-02-09 |
EP3875458A1 (en) | 2021-09-08 |
AU2019373702A1 (en) | 2021-06-24 |
WO2020088357A1 (zh) | 2020-05-07 |
CN111138301A (zh) | 2020-05-12 |
US20210387941A1 (en) | 2021-12-16 |
KR20210089195A (ko) | 2021-07-15 |
EP3875458A4 (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111138301B (zh) | 联苯类化合物、其中间体、制备方法、药物组合物及应用 | |
KR102482673B1 (ko) | 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도 | |
JP7293560B2 (ja) | 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用 | |
TWI675026B (zh) | 稠環衍生物、其製備方法、中間體、藥物組合物及應用 | |
TW201725207A (zh) | 一種btk激酶抑制劑的結晶形式及其製備方法 | |
EA029497B1 (ru) | Производные бензимидазолона в качестве ингибиторов бромодомена | |
TWI788424B (zh) | 受體抑制劑的并環類衍生物 | |
EP3010903A1 (en) | Olefin substituted oxindoles having ampk activity | |
WO2015024448A1 (zh) | 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用 | |
EP3010905A1 (en) | Spiro-substituted oxindole derivatives having ampk activity | |
JP2022527892A (ja) | 小分子pd-1/pd-l1阻害剤、pd-l1抗体との医薬組成物及びその使用 | |
JP2010535831A (ja) | デュシェンヌ型筋ジストロフィーの治療 | |
CN115991706A (zh) | Pim激酶抑制剂 | |
JP6199406B2 (ja) | ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物 | |
TWI833829B (zh) | 聯苯類化合物,其中間體,製備方法,藥物組合物及應用 | |
KR102666727B1 (ko) | 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도 | |
KR102406246B1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
TW202320762A (zh) | 氘化化合物 | |
CN118026948A (zh) | 三联芳环类化合物及其制备方法、药物组合物和应用 | |
WO2019141095A1 (zh) | 脒类和胍类衍生物、其制备方法及其在医药上的应用 | |
JPS5913513B2 (ja) | シンキシツフエンキカゴウブツ ノ セイゾウホウ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |